<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">96790</article-id><article-id pub-id-type="doi">10.7554/eLife.96790</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.96790.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>The common <italic>Sting1 HAQ, AQ</italic> alleles rescue CD4 T cellpenia, restore T-regs, and prevent <italic>SAVI (N153S</italic>) inflammatory disease in mice</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Aybar-Torres</surname><given-names>Alexandra a</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Saldarriaga</surname><given-names>Lennon A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Pham</surname><given-names>Ann T</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Emtiazjoo</surname><given-names>Amir M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Ashish K</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Bryant</surname><given-names>Andrew j</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Jin</surname><given-names>Lei</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6836-1142</contrib-id><email>lei.jin@medicine.ufl.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02y3ad647</institution-id><institution>Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Florida</institution></institution-wrap><addr-line><named-content content-type="city">Gainesville</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02y3ad647</institution-id><institution>Division of Vascular Surgery &amp; Endovascular Therapy, Department of Surgery, University of Florida</institution></institution-wrap><addr-line><named-content content-type="city">Gainesville</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Rothlin</surname><given-names>Carla V</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03v76x132</institution-id><institution>Yale University</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Rothlin</surname><given-names>Carla V</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03v76x132</institution-id><institution>Yale University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>18</day><month>09</month><year>2024</year></pub-date><volume>13</volume><elocation-id>RP96790</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-03-24"><day>24</day><month>03</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-03-24"><day>24</day><month>03</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.10.05.561109"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-06-13"><day>13</day><month>06</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.96790.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-08-19"><day>19</day><month>08</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.96790.2"/></event></pub-history><permissions><copyright-statement>© 2024, Aybar-Torres et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Aybar-Torres et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-96790-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-96790-figures-v1.pdf"/><abstract><p>The significance of <italic>STING1</italic> gene in tissue inflammation and cancer immunotherapy has been increasingly recognized. Intriguingly, common human <italic>STING1</italic> alleles R71H-G230A-R293Q (<italic>HAQ</italic>) and G230A-R293Q (<italic>AQ</italic>) are carried by ~60% of East Asians and ~40% of Africans, respectively. Here, we examine the modulatory effects of <italic>HAQ, AQ</italic> alleles on STING-associated vasculopathy with onset in infancy (SAVI), an autosomal dominant, fatal inflammatory disease caused by gain-of-function human <italic>STING1</italic> mutations. CD4 T cellpenia is evident in SAVI patients and mouse models. Using <italic>Sting1</italic> knock-in mice expressing common human <italic>STING1</italic> alleles <italic>HAQ</italic>, <italic>AQ</italic>, and <italic>Q293</italic>, we found that <italic>HAQ, AQ</italic>, and <italic>Q293</italic> splenocytes resist STING1-mediated cell death ex vivo, establishing a critical role of STING1 residue 293 in cell death. The <italic>HAQ/SAVI(N153S</italic>) and <italic>AQ/SAVI(N153S</italic>) mice did not have CD4 T cellpenia. The <italic>HAQ/SAVI(N153S), AQ/SAVI(N153S</italic>) mice have more (~10-fold, ~20-fold, respectively) T-regs than <italic>WT/SAVI(N153S</italic>) mice. Remarkably, while they have comparable TBK1, IRF3, and NFκB activation as the <italic>WT/SAVI</italic>, the <italic>AQ/SAVI</italic> mice have no tissue inflammation, regular body weight, and normal lifespan. We propose that STING1 activation promotes tissue inflammation by depleting T-regs cells in vivo. Billions of modern humans have the dominant <italic>HAQ, AQ</italic> alleles. STING1 research and STING1-targeting immunotherapy should consider <italic>STING1</italic> heterogeneity in humans.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>STING</kwd><kwd>SAVI</kwd><kwd>chronic inflammation</kwd><kwd>regulatory T cells</kwd><kwd>cell death</kwd><kwd>T cellpenia</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>HL152163</award-id><principal-award-recipient><name><surname>Jin</surname><given-names>Lei</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The common human <italic>HAQ,AQ</italic> alleles suppress <italic>STING1</italic> gain-of-function mutation-induced chronic STING1 inflammation in mice.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>STING1 drives cytosolic DNA-induced type I IFNs production (<xref ref-type="bibr" rid="bib4">Barber, 2015</xref>). Recent research revealed that STING1 promotes inflammation in a variety of inflammatory diseases, including nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, kidney injury, neurodegenerative diseases, cardiovascular diseases, obesity, diabetes, and aging (<xref ref-type="bibr" rid="bib57">Skopelja-Gardner et al., 2022</xref>; <xref ref-type="bibr" rid="bib2">Bai and Liu, 2021</xref>; <xref ref-type="bibr" rid="bib31">Li et al., 2023</xref>; <xref ref-type="bibr" rid="bib18">Gulen et al., 2023</xref>; <xref ref-type="bibr" rid="bib60">Szego et al., 2022</xref>; <xref ref-type="bibr" rid="bib14">Gao et al., 2023b</xref>; <xref ref-type="bibr" rid="bib69">Yan et al., 2022</xref>; <xref ref-type="bibr" rid="bib13">Gao et al., 2023a</xref>). The type I IFNs-independent function of STING1 has also emerged (<xref ref-type="bibr" rid="bib13">Gao et al., 2023a</xref>; <xref ref-type="bibr" rid="bib68">Yamashiro et al., 2020</xref>; <xref ref-type="bibr" rid="bib67">Wu et al., 2020</xref>; <xref ref-type="bibr" rid="bib50">Pham et al., 2024</xref>). For example, initially described as a type I interferonopathy (<xref ref-type="bibr" rid="bib32">Liu et al., 2014</xref>), recent studies in STING-associated vasculopathy with onset in infancy (SAVI) mouse models showed that SAVI is largely independent of type I IFNs (<xref ref-type="bibr" rid="bib35">Luksch et al., 2019</xref>; <xref ref-type="bibr" rid="bib59">Stinson et al., 2022</xref>; <xref ref-type="bibr" rid="bib65">Warner et al., 2017</xref>; <xref ref-type="bibr" rid="bib10">Frémond et al., 2021</xref>). In a <italic>Sting1 N153S</italic> mouse model of SAVI, crossing <italic>N153S</italic> mice to IRF3/IRF7, and IFNAR1 knockout mice, N153S mice still developed spontaneous lung diseases (<xref ref-type="bibr" rid="bib35">Luksch et al., 2019</xref>). JAK inhibitors were used to block type I IFNs signaling for SAVI patients with mixed success (<xref ref-type="bibr" rid="bib10">Frémond et al., 2021</xref>; <xref ref-type="bibr" rid="bib26">Kim et al., 2022</xref>; <xref ref-type="bibr" rid="bib64">Volpi et al., 2019</xref>; <xref ref-type="bibr" rid="bib62">Tang et al., 2020</xref>). For example, in a review of JAK inhibition in 18 SAVI patients, incomplete response to treatment happened in 7/18 (38%) of patients (<xref ref-type="bibr" rid="bib8">Dai et al., 2020</xref>). Furthermore, two patients died of respiratory failure despite this treatment (<xref ref-type="bibr" rid="bib8">Dai et al., 2020</xref>). Both radioresistant parenchymal and/or stromal cells and hematopoietic cells influence SAVI pathology in mice (<xref ref-type="bibr" rid="bib15">Gao et al., 2024</xref>; <xref ref-type="bibr" rid="bib12">Gao et al., 2022</xref>). The observation is important because it predicts that allogeneic stem cell transplantation may not work in human SAVI patients. Indeed, lung transplantations did not show improvement in SAVI patients (<xref ref-type="bibr" rid="bib26">Kim et al., 2022</xref>; <xref ref-type="bibr" rid="bib51">Picard et al., 2016</xref>). Patients died at 3- and 9 months post-lung transplant (<xref ref-type="bibr" rid="bib26">Kim et al., 2022</xref>; <xref ref-type="bibr" rid="bib51">Picard et al., 2016</xref>). How STING1 drives inflammation in vivo, independent of type I IFNs, remains unknown. Consequently, SAVI has no curative care.</p><p>Characterized as an innate immune sensor, STING1 expression is, paradoxically, high in CD4 T cells (<xref ref-type="bibr" rid="bib32">Liu et al., 2014</xref>; <xref ref-type="bibr" rid="bib24">Jin et al., 2013</xref>). Furthermore, STING1 activation kills mouse and human CD4 T cells ex vivo (<xref ref-type="bibr" rid="bib29">Larkin et al., 2017</xref>; <xref ref-type="bibr" rid="bib6">Cerboni et al., 2017</xref>; <xref ref-type="bibr" rid="bib28">Kuhl et al., 2023</xref>). SAVI patients and mouse models had CD4 T cellpenia (<xref ref-type="bibr" rid="bib32">Liu et al., 2014</xref>; <xref ref-type="bibr" rid="bib28">Kuhl et al., 2023</xref>). STING1 was first discovered as MPYS for its cell growth inhibition and cell death function in mouse B lymphoma cells (<xref ref-type="bibr" rid="bib22">Jin et al., 2008</xref>). STING1-mediated cell death is cell type dependent. For example, while STING1 activation kills human endothelial cells, primary and cancerous T cells, it does not kill mouse MEFs, BMDCs, or BMDMs (<xref ref-type="bibr" rid="bib17">Gulen et al., 2017</xref>; <xref ref-type="bibr" rid="bib25">Kabelitz et al., 2022</xref>; <xref ref-type="bibr" rid="bib45">Murthy et al., 2020</xref>). Second, STING1-mediated cell death is type I IFNs-independent (<xref ref-type="bibr" rid="bib28">Kuhl et al., 2023</xref>; <xref ref-type="bibr" rid="bib17">Gulen et al., 2017</xref>; <xref ref-type="bibr" rid="bib45">Murthy et al., 2020</xref>). Multiple cell death pathways, that is apoptosis, necroptosis, pyroptosis, ferroptosis, and PANoptosis, are proposed (<xref ref-type="bibr" rid="bib45">Murthy et al., 2020</xref>; <xref ref-type="bibr" rid="bib30">Li et al., 2021</xref>; <xref ref-type="bibr" rid="bib58">Song et al., 2022</xref>). Last, the in vivo biological significance of STING1-mediated CD4 T cell death is not clear (<xref ref-type="bibr" rid="bib28">Kuhl et al., 2023</xref>; <xref ref-type="bibr" rid="bib45">Murthy et al., 2020</xref>). In humans, SAVI patients with constitutively activated STING1 have low CD4 T cell numbers (<xref ref-type="bibr" rid="bib32">Liu et al., 2014</xref>), and type I IFNs are dispensable for STING1-mediated human CD4 T cell death (<xref ref-type="bibr" rid="bib28">Kuhl et al., 2023</xref>). Different from SAVI mice, SAVI patients (<italic>N154S</italic> or <italic>V155M</italic>) had normal counts of CD8 T and B cells (<xref ref-type="bibr" rid="bib32">Liu et al., 2014</xref>).</p><p>The human <italic>STING1</italic> gene is highly heterogeneous (<xref ref-type="bibr" rid="bib23">Jin et al., 2011</xref>; <xref ref-type="bibr" rid="bib47">Patel et al., 2017a</xref>). Approximately 50% of people in the U.S. carry at least one copy of non-<italic>WT STING1</italic> allele (<xref ref-type="bibr" rid="bib23">Jin et al., 2011</xref>). Among them, the R71H-G230A-R293Q (<italic>HAQ</italic>) is the second most common <italic>STING1</italic> allele carried by ~23% of people in the U.S. (<xref ref-type="bibr" rid="bib23">Jin et al., 2011</xref>). However, in East Asians, <italic>WT/HAQ</italic> (34.3%), not <italic>WT/WT</italic> (22.0%), is the most common <italic>STING1</italic> genotype (<xref ref-type="bibr" rid="bib47">Patel et al., 2017a</xref>). Critically, the <italic>HAQ</italic> allele was positively selected in modern humans outside Africa <xref ref-type="bibr" rid="bib37">Mansouri et al., 2022</xref>. Anatomically modern humans outside Africa are descendants of a single Out-of-Africa Migration 50,000~70,000 years ago. ~1.4% of Africans have the <italic>HAQ</italic> allele, while ~63.9% of East Asians are <italic>HAQ</italic> carriers (<xref ref-type="bibr" rid="bib37">Mansouri et al., 2022</xref>). Haplotype analysis revealed that <italic>HAQ</italic> was derived from G230A-R293Q (<italic>AQ</italic>) allele (<xref ref-type="bibr" rid="bib37">Mansouri et al., 2022</xref>). Importantly, the <italic>AQ</italic> allele was negatively selected outside Africa (<xref ref-type="bibr" rid="bib37">Mansouri et al., 2022</xref>). Approximately 40.1% of Africans are <italic>AQ</italic> carriers, while ~0.4% of East Asians have the <italic>AQ</italic> allele (<xref ref-type="bibr" rid="bib37">Mansouri et al., 2022</xref>). <italic>STING1</italic> alleles often have a dominant negative effect likely because the protein STING1 exists as a homodimer (<xref ref-type="bibr" rid="bib22">Jin et al., 2008</xref>; <xref ref-type="bibr" rid="bib49">Patel and Jin, 2019</xref>). SAVI is an autosomal dominant inflammatory disease (<xref ref-type="bibr" rid="bib32">Liu et al., 2014</xref>). <italic>WT/HAQ</italic> individuals had reduced Pneumovax23-induced antibody responses compared to <italic>WT/WT</italic> individuals (NCT02471014) (<xref ref-type="bibr" rid="bib55">Sebastian et al., 2020</xref>). Notably, <italic>AQ</italic> responds to CDNs and produces type I IFNs in vivo and in vitro (<xref ref-type="bibr" rid="bib37">Mansouri et al., 2022</xref>; <xref ref-type="bibr" rid="bib70">Yi et al., 2013</xref>; <xref ref-type="bibr" rid="bib48">Patel et al., 2017b</xref>), but the <italic>AQ</italic> allele was negatively selected in non-Africans (<xref ref-type="bibr" rid="bib37">Mansouri et al., 2022</xref>). In contrast, the <italic>HAQ</italic> allele, defective in CDNs-type I IFNs responses (<xref ref-type="bibr" rid="bib23">Jin et al., 2011</xref>; <xref ref-type="bibr" rid="bib47">Patel et al., 2017a</xref>; <xref ref-type="bibr" rid="bib55">Sebastian et al., 2020</xref>; <xref ref-type="bibr" rid="bib46">Nissen et al., 2018</xref>; <xref ref-type="bibr" rid="bib53">Ruiz-Moreno et al., 2018</xref>), was positively selected in non-Africans (<xref ref-type="bibr" rid="bib37">Mansouri et al., 2022</xref>), indicating that the CDNs-type I IFNs independent function of STING1 was essential for the survival of early modern humans outside of Africa.</p><p>In this study, we discovered, surprisingly, that the <italic>HAQ</italic>, <italic>AQ</italic> splenocytes are resistant to STING1-mediated cell death. We generated <italic>HAQ/SAVI(N153S</italic>) and <italic>AQ/SAVI(N153S</italic>) mice and found that the <italic>HAQ, AQ</italic> alleles prevent CD4 T cellpenia, increasing/restoring T-regs and alleviating/stopping tissue inflammation in SAVI mice, thus providing evidence for the in vivo significance of type I IFNs-independent, STING1-mediated cell death and potential <italic>AQ</italic>-based curative therapy for SAVI patients.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>STING1 activation kills mouse spleen CD4, CD8 T, and CD19 B cells ex vivo</title><p>We first used the synthetic non-CDNs STING1 agonist diABZI (<xref ref-type="bibr" rid="bib52">Ramanjulu et al., 2018</xref>) to induce lymphocyte death because diABZI induces cell death without the need for lipid transfection or detergent for cell permeabilization (<xref ref-type="bibr" rid="bib25">Kabelitz et al., 2022</xref>; <xref ref-type="bibr" rid="bib40">Messaoud-Nacer et al., 2022</xref>) and diABZI is in clinical trials (NCT05514717). Splenocytes from C57BL/6 N mice were treated with diABZI in culture, and cell death was determined by Annexin V and Propidium Iodide stain. Splenocyte cell death could be detected at 5 hr post diABZI treatment (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). Dosage responses showed that ~25 ng/ml diABZI could kill 70% of splenocytes (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). Similarly, STING1 agonists DMXAA and synthetic CDNs RpRpss-Cyclic di-AMP killed mouse spleen CD4, CD8 T cells, and CD19 B cells (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Thus, STING1 activation readily induces mouse lymphocyte death ex vivo.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Splenocytes from <italic>HAQ, AQ</italic>, and <italic>Q293</italic> mice are resistant to STING1-mediated cell death ex vivo.</title><p>(<bold>A</bold>) C57BL/6 N splenocytes were treated directly (no transfection) with diABZI (100 ng/ml), RpRpss-Cyclic di-AMP (5 μg/ml) or 2′3′-cGAMP (10 μg/ml), DMXAA (25 μg/ml) for 24 hr in culture. CD4, CD8 T cells and CD19 B cells death were determined by PI staining. (<bold>B</bold>). Splenocytes from C57BL/6 N mice were pre-treated with indicated small molecules, GSK2334470 (1.25 µM), GSK8612 (2.5 µM), Bx-795 (0.5 µM), QVD-OPH (25 µM) for 2 hrs. diABZI (100 ng/ml) was added in culture for another 24 hr. Dead cells were determined by PI staining. (<bold>C–D</bold>). Flowcytometry of <italic>HAQ</italic>, <italic>AQ</italic>, <italic>IFNAR1</italic><sup><italic>-/-</italic></sup> or C57BL/6 N splenocytes treated with diABZI (100 ng/ml) for 24 hrs. Cell death was determined by PI staining. (<bold>E–F</bold>). <italic>Q293</italic> or the <italic>WT</italic> littermates splenocytes were treated with diABZI (100 ng/ml), RpRpss-Cyclic di-AMP (5 μg/ml) or 2′3′-cGAMP 10 μg/ml for 24 hr. Cell death was determined by PI staining. (<bold>G</bold>). <italic>WT/HAQ</italic>, <italic>WT/AQ</italic>, or <italic>WT/WT</italic> littermates splenocytes were treated with DMXAA (10, 25 or 100 µg/ml) for 24 hr. Cell death was determined by PI staining. Data are representative of three independent experiments. Graphs represent the mean with error bars indication s.e.m. <italic>p</italic> values are determined by one-way ANOVA Tukey’s multiple comparison test (<bold>A, E, G</bold>) or unpaired student T-test (<bold>B, D</bold>) * p&lt;0.05. n.s: not significant.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96790-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Bx-795 inhibits diABZI-induced mouse splenocyte death.</title><p>(<bold>A</bold>) Splenocytes from C57BL/6N mice were treated with 100ng/ml diABZI in culture for the indicated time. Dead cells were determined by PI and Annexin V staining. (<bold>B</bold>) Splenocytes from C57BL/6N mice were treated with indicated dose of diABZi in culture for 24hrs. Dead cells were determined by PI staining. (<bold>C</bold>) Splenocytes from C57BL/6N mice were pre-treated with indicated small molecules, H151 (10µg/ml), C176 (1µM), MCC950 (1.25µM), 2-BP (20µM), GSK872 (312.5nM), Liproxstatin-1 (1µM), necrostatin-1 (10µM), VX-765 (1µM), Z-DEVD-FMK (25µM), Bx-795 (0.5µM) for 2 hr. diABZi (100ng/ml) was added in culture for another 24 hr. Dead cells were determined by PI staining. (D) IFNβ was determined in the cell supernatant from C by ELISA. Data are representative of three independent experiments. Graphs represent the mean with error bars indication s.e.m. n=3~5 mice/group. p values are determined by one-way ANOVA Tukey’s multiple comparison test (<bold>A, D</bold>) or unpaired student T-test (C). * p.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96790-fig1-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-2"><title>TBK1 activation is required for STING1-mediated mouse spleen cell death ex vivo</title><p>STING1 activation can lead to apoptosis, pyroptosis, necroptosis, or ferroptosis (<xref ref-type="bibr" rid="bib28">Kuhl et al., 2023</xref>; <xref ref-type="bibr" rid="bib22">Jin et al., 2008</xref>; <xref ref-type="bibr" rid="bib17">Gulen et al., 2017</xref>; <xref ref-type="bibr" rid="bib25">Kabelitz et al., 2022</xref>; <xref ref-type="bibr" rid="bib45">Murthy et al., 2020</xref>; <xref ref-type="bibr" rid="bib30">Li et al., 2021</xref>; <xref ref-type="bibr" rid="bib58">Song et al., 2022</xref>; <xref ref-type="bibr" rid="bib40">Messaoud-Nacer et al., 2022</xref>; <xref ref-type="bibr" rid="bib61">Tang et al., 2016</xref>). We then treated mouse splenocytes with apoptosis, pyroptosis, necroptosis inhibitors, STING1 inhibitors H-151, C-176, and palmitoylation inhibitor 2-bromopalmitate (2 BP), followed by diABZI stimulation. Inhibitors for NLRP3 (MCC950), RIPK1 (Necrostatin-1), RIPK3 (GSK872), Caspase-1 (VX-795), Caspase-3 (Z-DEVD-FMK), Caspase 1,3,8,9 (Q-VD-Oph), ferroptosis (liproxstatin-1) did not affect diABZI-induced splenocyte cell death ex vivo (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B, C</xref>). The STING1 inhibitors H-151, C-176, and 2 BP also could not prevent diABZI-induced cell death (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>), although they inhibited diABZI-induced IFNβ production (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>). Instead, the TBK1 inhibitor BX-795 abolished diABZI-induced splenocyte death (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>).</p><p>BX-795 is a multi-kinase inhibitor, including 3-phosphoinositide-dependent protein kinase 1 (PDK1) and TBK1 (IC<sub>50s</sub> = 6 and 11 nM, respectively). However, the treatment of PDK1 inhibitor GSK2334470 (IC50=10 nM) did not prevent diABZI-induced splenocyte death (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). In contrast, GSK8612, a highly potent and selective inhibitor for TBK1, prevented diABZI-induced splenocyte death (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Thus, TBK1 activation is likely critical for STING1-mediated splenocyte cell death ex vivo.</p></sec><sec id="s2-3"><title><italic>HAQ, AQ, Q293 STING1</italic> knock-in mouse splenocytes are resistant to STING1-mediated cell death ex vivo</title><p><italic>HAQ</italic> and <italic>AQ</italic> are common human <italic>STING1</italic> alleles (<xref ref-type="bibr" rid="bib23">Jin et al., 2011</xref>; <xref ref-type="bibr" rid="bib47">Patel et al., 2017a</xref>; <xref ref-type="bibr" rid="bib37">Mansouri et al., 2022</xref>). Previously, we reported that <italic>HAQ</italic> knock-in mice are defective in CDNs-induced immune responses, while CDNs responses in <italic>AQ</italic> knock-in mice are similar to WT mice (<xref ref-type="bibr" rid="bib37">Mansouri et al., 2022</xref>). We treated splenocytes from <italic>HAQ</italic> and <italic>AQ</italic> mice with diABZI ex vivo and found, surprisingly, that both <italic>HAQ</italic> and <italic>AQ</italic> splenocytes were resistant to diABZI-induced cell death (<xref ref-type="fig" rid="fig1">Figure 1C and D</xref>). In comparison, <italic>IFNAR1</italic><sup><italic>-/-</italic></sup> splenocytes were killed by diABZI, confirming that STING1-mediated lymphocytes death are type I IFNs-independent (<xref ref-type="fig" rid="fig1">Figure 1C and D</xref>; <xref ref-type="bibr" rid="bib28">Kuhl et al., 2023</xref>; <xref ref-type="bibr" rid="bib17">Gulen et al., 2017</xref>; <xref ref-type="bibr" rid="bib45">Murthy et al., 2020</xref>).</p><p><italic>HAQ</italic> and <italic>AQ</italic> share the common A230 and Q293 residues changes. We thus generated a <italic>Q293 Sting1</italic> knock-in mouse. Notably, the Q293 splenocytes were resistant to STING1 agonists 2’3’-cGAMP, RpRpss-Cyclic di-AMP, and diABZI-induced cell death (<xref ref-type="fig" rid="fig1">Figure 1E and F</xref>). Thus, the residue 293 of STING1 is critical for its cell death function.</p></sec><sec id="s2-4"><title><italic>WT/HAQ</italic>, <italic>WT/AQ</italic> mouse splenocytes are partially resistant to STING1-mediated cell death ex vivo</title><p><italic>WT/HAQ</italic> (34.3%) is the most common human <italic>STING1</italic> genotype in East Asians, while <italic>WT/AQ</italic> (28.2%) is the 2<sup>nd</sup> most common <italic>STING1</italic> genotype in Africans (<xref ref-type="bibr" rid="bib47">Patel et al., 2017a</xref>). We generated <italic>WT/HAQ</italic>, <italic>WT/AQ</italic> mice and treated their splenocytes with mouse STING1 agonist DMXAA. <italic>WT/HAQ</italic> and <italic>WT/AQ</italic> splenocytes were protected from 25 µg/ml DMXAA-induced cell death (<xref ref-type="fig" rid="fig1">Figure 1G</xref>). A total of 100 µg/ml DMXAA could kill <italic>WT/HAQ</italic> and <italic>WT/AQ</italic> splenocytes, albeit less than <italic>WT/WT</italic> cells (<xref ref-type="fig" rid="fig1">Figure 1G</xref>). Thus, the <italic>HAQ</italic> and <italic>AQ</italic> alleles are dominant and likely impact STING1 activation even in heterozygosity.</p></sec><sec id="s2-5"><title>STING1 activation kills primary human CD4 T cells but not CD8 T or CD19 B cells</title><p>STING1 agonists-based clinical trials in humans have been disappointing (NCT02675439, NCT03010176, NCT05514717; <xref ref-type="bibr" rid="bib39">Meric-Bernstam et al., 2023</xref>; <xref ref-type="bibr" rid="bib38">Meric-Bernstam et al., 2022</xref>). We showed that the human <italic>STING1</italic> gene might undergo natural selection during the out-of-Africa migration (<xref ref-type="bibr" rid="bib37">Mansouri et al., 2022</xref>) sensitive to evolutionary pressure. Thus, we investigated STING1-mediated death in primary human lymphocytes.</p><p>Human explant lung cells from the <italic>WT(R232)/WT(R232</italic>) donors were treated with STING1 agonists 2’3 c GAMP, RpRpss-Cyclic di-AMP, diABZI for 24 hr in culture. Lymphocyte cell death was determined by Propidium Iodide staining. Different from mouse lymphocytes, diABZI and RpRpss-Cyclic di-AMP killed human CD4 T but not CD8 T or CD19 B cells (<xref ref-type="fig" rid="fig2">Figure 2A and B</xref>). Human CD8 T and CD19 B cells are resistant to 500 ng/ml diABZI-induced cell death (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title><italic>HAQ</italic>, <italic>AQ</italic>, and <italic>Q293</italic> human cells are resistant to STING1 agonists-induced death.</title><p>(<bold>A–B</bold>) Total human Lung cells from <italic>WT/WT</italic> individuals were treated with diABZi (100 ng/ml) for 24 hr. Cell death in CD4, CD8 T cells and CD19 B cells were determined by PI staining. (<bold>C</bold>). Total lung cells from a <italic>WT/HAQ</italic> (2 individuals) and a <italic>WT/WT</italic> (3 individuals) were treated with diABZi (25, 100 ng/ml) for 24 hr. Cell death in CD4 T cells was determined by PI staining. (<bold>D–E</bold>). STING1-KO THP-1 cells (Invivogen,, cat no. thpd-kostg) were stably reconstituted with human <italic>WT (R232), HAQ</italic>, <italic>AQ</italic>, <italic>Q293</italic>. Cells were treated with diABZI (200 ng/ml) in culture for 24 hr. Dead cells were determined by Annexin V staining. (<bold>F</bold>). STING1-KO THP-1 cells stably reconstituted with human <italic>WT (R232), Q293</italic> were treated with indicated dose of diABZI for 24 hr in culture. Dead cells were determined by Annexin V staining. (<bold>G</bold>). STING1-KO THP-1 cells stably reconstituted with human <italic>WT (R232), Q293</italic> were treated with indicated dose of diABZI for 2hs in culture. STING1 activation was detected by anti-STING1 antibody (Proteintech, #19851–1-AP). (<bold>H</bold>). STING1-KO THP-1 cells stably reconstituted with human <italic>WT (R232), HAQ</italic>, <italic>AQ</italic>, <italic>Q293</italic> were treated with 50 ng/ml diABZI in culture for 24 hr. ISG-54 reporter luciferase activity was determined in cell supernatant and normalized to 10 ng/ml IFNβ-stimulated ISG-54 luciferase activity. (<bold>I</bold>). STING1-KO THP-1 cells stably reconstituted with human <italic>WT (R232), HAQ</italic>, <italic>AQ</italic> were treated with 50 ng/ml diABZI in culture for 2 hr. STING1 and IRF3 activation were determined by anti-STING1 antibody and anti-p IRF3 antibody (CST, Ser396, clone 4D4G). Densitometry was determined by ImageLab 5. Data are representative of three independent experiments. Graphs represent the mean with error bars indication s.e.m. p values determined by one-way ANOVA Tukey’s multiple comparison test (<bold>B, C, F, H, G</bold>) or unpaired student T-test (<bold>E, I</bold>). * p&lt;0.05, n.s: not significant.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96790-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>STING1 activation in primary human cells and THP-1 cells reconstituted with <italic>WT</italic> human <italic>STING1</italic>.</title><p>(<bold>A</bold>). Total human Lung cells from <italic>WT/WT</italic> individuals were treated with indicated dose of diABZi for 24 hr. Cell death in CD4, CD8 T cells and CD19 B cells were determined by PI staining. (<bold>B</bold>). Sequencing results of human <italic>STING1</italic> gene in <italic>WT/WT</italic> and <italic>WT/HAQ</italic> individuals. (<bold>C–D</bold>). STING1-KO THP-1 cells stably reconstituted with human <italic>WT (R232</italic>) were treated with indicated dose of diABZI for indicated time in culture. ISG-54 reporter luciferase activity was determined in cell supernatant and normalized to 10 ng/ml IFNβ-stimulated ISG-54 luciferase activity. Data are representative of at least two independent experiments. Graphs represent the mean with error bars indication s.e.m. p values determined by one-way ANOVA Tukey’s multiple comparison test. * p&lt;0.05, n.s: not significant.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96790-fig2-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-6"><title><italic>WT/HAQ</italic> human CD4 T cells are resistant to low doses of diABZI-induced cell death</title><p><italic>WT/HAQ</italic> mouse splenocytes are resistant to low-dose diABZI-induced cell death (<xref ref-type="fig" rid="fig1">Figure 1G</xref>). To extend our observation into primary human T cells, we obtained lung explants from <italic>WT/WT</italic> and <italic>WT/HAQ</italic> individuals (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>) and treated them with diABZI in culture. 25 ng/ml diABZI killed <italic>WT/WT</italic>, but not <italic>WT/HAQ</italic>, human lung CD4 T cells (<xref ref-type="fig" rid="fig2">Figure 2C</xref>).</p></sec><sec id="s2-7"><title>diABZI induces cell death in <italic>STING1-</italic>KO human THP-1 cells reconstituted with <italic>WT</italic> human <italic>STING1 (R232</italic>) but not <italic>HAQ, AQ or Q293</italic> human <italic>STING1</italic> allele</title><p>To further determine cell death influenced by human <italic>STING1</italic> alleles <italic>HAQ, AQ,</italic> and <italic>Q293</italic>, we used the <italic>STING1-</italic>KO THP-1 cell line because STING1 agonist induces type I IFNs and cell death in <italic>STING1-</italic>KO THP-1 cells expressing <italic>WT</italic> human STING1 (<xref ref-type="bibr" rid="bib58">Song et al., 2022</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C and D</xref>). We, thus, generated stable THP-1 <italic>STING1-</italic>KO lines expressing <italic>HAQ, AQ, WT,</italic> or <italic>Q293 STING1</italic> allele. Cell death was determined by Annexin-V staining. diABZI killed THP-1 <italic>STING1-</italic>KO lines expressing <italic>WT</italic> but not <italic>HAQ, AQ,</italic> or <italic>Q293 STING1</italic> allele (<xref ref-type="fig" rid="fig2">Figure 2D and E</xref>). No cell death was induced in the <italic>Q293</italic> THP-1 cells stimulated by 20–200 ng/ml of diABZI (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). diABZI also did not induce STING1 activation in <italic>Q293</italic> THP-1 cells (<xref ref-type="fig" rid="fig2">Figure 2G</xref>). Notably, 50 ng/ml diABZI induced p-IRF3 activation and type I IFNs in <italic>AQ</italic> THP-1 cells but not <italic>HAQ</italic> THP-1 cells (<xref ref-type="fig" rid="fig2">Figure 2H and I</xref>), indicating that the STING1-cell death and STING1-IRF3-Type I IFNs pathways can be uncoupled.</p></sec><sec id="s2-8"><title><italic>HAQ</italic> and <italic>AQ</italic> alleles rescue the lymphopenia and suppress myeloid cell expansion in <italic>SAVI(N153S</italic>) mice</title><p>The in vivo significance of the STING1/MPYS-cell death is unclear. Furthermore, multiple cell death pathways, that is apoptosis, necroptosis, pyroptosis, ferroptosis, and PANoptosis, are proposed (<xref ref-type="bibr" rid="bib45">Murthy et al., 2020</xref>; <xref ref-type="bibr" rid="bib30">Li et al., 2021</xref>; <xref ref-type="bibr" rid="bib58">Song et al., 2022</xref>). The uncertainty likely results from studies using different cell types (primary cells vs cancer cell lines); species (human vs mouse); STING1 agonists (cGAMP, which requires cell permeabilization by detergents or lipid transfection, vs diABZi, DMXAA that can directly cross the membrane; <xref ref-type="bibr" rid="bib29">Larkin et al., 2017</xref>; <xref ref-type="bibr" rid="bib6">Cerboni et al., 2017</xref>; <xref ref-type="bibr" rid="bib17">Gulen et al., 2017</xref>; <xref ref-type="bibr" rid="bib25">Kabelitz et al., 2022</xref>; <xref ref-type="bibr" rid="bib66">Wu et al., 2019</xref>). Critically, which mechanism is relevant in vivo, causing T cellpenia is not known. To clarify the in vivo significance and mechanisms of STING1-mediated cell death, we turned to SAVI mice.</p><p>SAVI is an autosomal dominant, inflammatory disease caused by one copy of a gain-of-function <italic>STING1</italic> mutant (<italic>WT/SAVI</italic>) <xref ref-type="bibr" rid="bib32">Liu et al., 2014</xref>). CD4 T cellpenia was found in SAVI patients and SAVI mouse models (<xref ref-type="bibr" rid="bib32">Liu et al., 2014</xref>; <xref ref-type="bibr" rid="bib35">Luksch et al., 2019</xref>. STING1 activation in SAVI mice is independent of ligands and happens in vivo. We thus generated <italic>HAQ/SAVI(N153S</italic>) and <italic>AQ/SAVI(N153S</italic>) mice aiming to establish the in vivo significance and mechanism of STING1-cell death.</p><p>First, <italic>HAQ/SAVI(N153S</italic>) and <italic>AQ/SAVI(N153S</italic>) mice had reduced splenomegaly compared to <italic>WT/SAVI(N153S</italic>) mice though their spleens were still larger than the littermates <italic>WT/HAQ</italic> and <italic>WT/AQ</italic> (<xref ref-type="fig" rid="fig3">Figure 3A and B</xref>). Next, <italic>HAQ/SAVI(N153S</italic>) and <italic>AQ/SAVI(N153S</italic>) mice had similar spleen B cells and CD4 T cell numbers as the <italic>WT/HAQ</italic>, <italic>WT/AQ</italic> littermates (<xref ref-type="fig" rid="fig2">Figure 2B and C</xref>). Their CD8<sup>+</sup> T cells were lower than their <italic>WT</italic> littermates but much higher than the <italic>WT/SAVI(N153S</italic>) mice (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Third, spleen myeloid cell numbers, that is neutrophils, Ly6C<sup>hi</sup> monocytes and F4/80 macrophages, were all reduced by half compared to <italic>WT/SAVI(N153S</italic>) mice (<xref ref-type="fig" rid="fig3">Figure 3E, H</xref>). Last, splenocytes from <italic>HAQ/SAVI</italic>, <italic>AQ/SAVI</italic> mice were partially resistant to diABZI, DMXAA-induced cell death ex vivo (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). Notably, the <italic>HAQ/SAVI(N153S</italic>) and <italic>AQ/SAVI(N153S</italic>) mice also had restored bone marrow monocytes (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). Thus, <italic>HAQ</italic> and <italic>AQ</italic> alleles prevent lymphopenia and suppress myeloid cell expansion in <italic>SAVI(N153S</italic>) mice.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title><italic>HAQ</italic> and <italic>AQ</italic> rescue the lymphopenia and suppress myeloid cell expansion in <italic>SAVI (N153S</italic>) mice.</title><p>(<bold>A</bold>) The size and weight of spleens from <italic>WT/HAQ, HAQ/SAVI, AQ/SAVI, WT/AQ, WT/SAVI</italic>. (<bold>B–D</bold>). Spleen CD19<sup>+</sup> B cells, CD4, CD8 T cells were determined in the indicated mice by Flow. (<bold>E–H</bold>). Spleen Ly6G<sup>+</sup> neutrophils, Ly6C<sup>hi</sup> monocytes and F4/80<sup>+</sup> macrophage was determined in the indicated mice by Flow. Data are representative of three independent experiments. n=3–5 mice/group. Graphs represent the mean with error bars indication s.e.m. p values are determined by one-way ANOVA Tukey’s multiple comparison test. * p&lt;0.05, n.s: not significant.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96790-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title><italic>Splenocytes from HAQ/SAVI, AQ/SAVI partially resist to STING1-activation-induced cell death</italic> ex vivo.</title><p>(<bold>A–B</bold>). Flow cytometry of <italic>HAQ/SAVI</italic>, <italic>AQ/SAVI</italic>, <italic>WT/WT</italic> or <italic>WT/HAQ</italic> splenocytes treated with diABZI (100 ng/ml) or DMXAA (20 µg/ml) for 24 hr. Cell death was determined by PI staining. Data are representative of three independent experiments. Graphs represent the mean with error bars indication s.e.m. p values are determined by one-way ANOVA Tukey’s multiple comparison test. * p&lt;0.05. n.s: not significant.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96790-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title><italic>HAQ</italic> and <italic>AQ</italic> restore bone marrow monocytes in <italic>SAVI (N153S</italic>) mice.</title><p>(<bold>A–D</bold>) Flow analysis of Ly6G<sup>+</sup>CD11B<sup>+</sup> neutrophils and Ly6G<sup>-</sup>Ly6C<sup>+</sup>CD11B<sup>+</sup> bone marrow monocytes from HAQ/SAVI, AQ/SAVI, WT/SAVI and their littermates. n=3–5 mice/group. Data are representative of three independent experiments. Graphs represent the mean with error bars indication s.e.m. p values are determined by one-way ANOVA Tukey’s multiple comparison test. * p&lt;0.05, n.s: not significant.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96790-fig3-figsupp2-v1.tif"/></fig></fig-group></sec><sec id="s2-9"><title>The <italic>HAQ</italic> allele alleviates and the <italic>AQ</italic> allele prevents <italic>SAVI(N153S</italic>) disease in mice</title><p><italic>SAVI(N153S</italic>) disease is characterized by early onset, failure to thrive (low body weight), persistent lung inflammation, decreased lung function, and young death in humans and mouse models <xref ref-type="bibr" rid="bib32">Liu et al., 2014</xref>; <xref ref-type="bibr" rid="bib10">Frémond et al., 2021</xref>; <xref ref-type="bibr" rid="bib66">Wu et al., 2019</xref>; <xref ref-type="bibr" rid="bib43">Motwani et al., 2019</xref>. The <italic>HAQ/SAVI(N153S</italic>) mice weighed more and had an improved lifespan than the <italic>WT/SAVI(N153S</italic>) mice (<xref ref-type="fig" rid="fig4">Figure 4A and B</xref>). The lifespan, airway resistance, and tissue inflammation (lung, liver) were also improved in <italic>HAQ/SAVI(N153S</italic>) mice compared to the <italic>WT/SAVI(N153S</italic>) mice (<xref ref-type="fig" rid="fig4">Figure 4C, D, J and K</xref>). However, the pulmonary artery pressure was still elevated in <italic>HAQ/SAVI(N153S</italic>) mice (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). Remarkably, the <italic>AQ/SAVI(N153S</italic>) mice had similar body weight and lifespan as the <italic>WT/AQ</italic> mice (<xref ref-type="fig" rid="fig4">Figure 4F and G</xref>). The airway resistance, pulmonary artery pressure, and tissue inflammation in <italic>AQ/SAVI(N153S</italic>) were similar to the <italic>WT/AQ</italic> littermates (<xref ref-type="fig" rid="fig4">Figure 4H, I, J and K</xref>). Thus, the <italic>HAQ</italic> allele alleviates and the <italic>AQ</italic> allele prevents inflammatory SAVI disease in mice. Interestingly, lungs from <italic>HAQ/SAVI, AQ/SAVI</italic> had similarly reduced infiltration of Ly6G<sup>+</sup>CD11B<sup>+</sup> neutrophils and Ly6G<sup>-</sup>Ly6C<sup>+</sup>CD11B<sup>+</sup> inflammatory monocytes compared to <italic>WT/SAVI</italic> mice (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title><italic>HAQ</italic> and <italic>AQ</italic> alleles prevent <italic>SAVI(N153S</italic>) disease in mice.</title><p>(<bold>A, B, G</bold>) The size and body weight of <italic>HAQ/SAVI</italic>, <italic>AQ/SAVI</italic>, <italic>WT/SAVI</italic> and their littermates <italic>WT/HAQ</italic>, <italic>WT/AQ</italic> mice. (<bold>D, E, H, I</bold>). Airway resistance, and pulmonary artery pressure were determined as described in Materials and methods. (<bold>C, F</bold>). <italic>HAQ/SAVI, AQ/SAVI, WT/SAVI</italic> (10 mice/group), were monitored for survival by Kaplan-Meier. (<bold>J, K</bold>). Representative hematoxylin and eosin (H&amp;E) staining of lung, liver sections from indicated mice. n=3–5 mice/group. Data are representative of three independent experiments. Graphs represent the mean with error bars indication s.e.m. p values are determined by one-way ANOVA Tukey’s multiple comparison test. * p&lt;0.05, **p&lt;0.01. n.s.: not significant. (WBC): white blood cells; <bold>H</bold>: hepatocytes; K: Kupper cells; PV: portal vein; CV: central vein.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96790-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title><italic>HAQ, AQ</italic> suppress lung myeloid cells infiltration in <italic>SAVI(N153S</italic>) mice.</title><p>(<bold>A–C</bold>) Flow analysis of lung Ly6G<sup>+</sup>CD11B<sup>+</sup> neutrophils and Ly6G<sup>-</sup>Ly6C<sup>+</sup>CD11B<sup>+</sup> monocytes from <italic>HAQ/SAVI, AQ/SAVI, WT/SAVI and their littermates WT/HAQ, WT/AQ</italic> mice. n=3–5 mice/group. Data are representative of three independent experiments. Graphs represent the mean with error bars indication s.e.m. p values are determined by one-way ANOVA Tukey’s multiple comparison test. * p&lt;0.05.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96790-fig4-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-10"><title>diABZI induces similar STING1, TBK1, IRF3, NFκB activation in the <italic>AQ/SAVI(N153S</italic>) and <italic>WT/SAVI(N153S</italic>) bone-marrow-derived-macrophage (BMDM)</title><p>SAVI was characterized as type I interferonopathy (<xref ref-type="bibr" rid="bib10">Frémond et al., 2021</xref>). However, several studies showed that type I IFN signaling and IRF3 activation were dispensable for SAVI disease (<xref ref-type="bibr" rid="bib35">Luksch et al., 2019</xref>; <xref ref-type="bibr" rid="bib59">Stinson et al., 2022</xref>; <xref ref-type="bibr" rid="bib12">Gao et al., 2022</xref>; <xref ref-type="bibr" rid="bib43">Motwani et al., 2019</xref>). <italic>AQ</italic> allele prevents SAVI disease (<xref ref-type="fig" rid="fig4">Figure 4</xref>). However, diABZI-treated <italic>AQ/SAVI(N153S</italic>) and <italic>WT/SAVI(N153S</italic>) BMDM had similar TBK1-IRF3 activation and IFNβ production (<xref ref-type="fig" rid="fig5">Figure 5A and B</xref>). diABZI treatment caused IκBα degradation, and similar TNF production in <italic>WT/SAVI</italic> and <italic>AQ/SAVI</italic> BMDM (<xref ref-type="fig" rid="fig5">Figure 5C and D</xref>). Furthermore, diABZI activation led to STING1 protein degradation in <italic>WT/SAVI</italic> and <italic>AQ/SAVI</italic> BMDM (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). Last, using cleavable crosslinker dithiobis succinimidyl propionate (DSP), we showed that STING1 in <italic>WT/SAVI, AQ/SAVI</italic> BMDM forms a similar dimer in situ (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). Thus, the <italic>AQ/SAVI</italic> BMDM had similar STING1 degradation, TBK1, IRF3, NFκB activation, and dimerization as the <italic>WT/SAVI</italic> BMDM.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title><italic>AQ/SAVI(N153S</italic>) cells had similar TBK1-IRF3, NFκB activation and STING1 degradation as the <italic>WT/SAVI(N153S</italic>) cells.</title><p>(<bold>A, C</bold>). BMDM from <italic>WT/WT, WT/SAVI, HAQ/SAVI</italic> and <italic>AQ/SAVI</italic> were treated with 100 ng/ml diABZi in culture for 2 hr. Cells were lysed and run on a 4~20% Mini-PROTEAN TGX Stain-Free Precast Gel. The blot was probed for phospho-Thr172-TBK1 antibody (CST, clone D52C2), phosphor-Ser 396-IRF3 (CST, clone 4D4G), STING1 (Proteintech, #19851–1-AP) and IκBα (CST, clone 44D4) antibody. (<bold>E</bold>). BMDM from <italic>WT/WT, WT/SAVI, HAQ/SAVI</italic> and <italic>AQ/SAVI</italic> were treated with 100 ng/ml diABZi in culture for 24 hr. Cells were lysed and run on a 4~20% Mini-PROTEAN TGX Stain-Free Precast Gel. The blot was probed for STING1 antibody (Proteintech, 19851–1-AP). (<bold>B, D</bold>). IFNβ and TNF were determined by ELISA in the cell supernatant from <bold>E</bold>. (<bold>F</bold>). BMDM from <italic>WT/WT, WT/SAVI, HAQ/SAVI</italic> and <italic>AQ/SAVI</italic> were treated with 400 µM cleavable chemical crosslinker DSP (Pierce, cat no: PG82081) in PBS for 1 hr at 4 °C. Cells were washed with PBS and lysed in RIPA buffer. Whole cell lysate was mixed with 4 x Laemmli Sample Buffer (BioRad, cat no 1610747) containing 5% 2-mercaptoethanol, heated at 95 °C for 10 min and, run on a 4~20% Mini-PROTEAN TGX Stain-Free Precast Gel. The blot was probed for STING1 antibody (Proteintech, 19851–1-AP). Densitometry was determined by ImageLab 5. Data are representative of three independent experiments. Graphs represent the mean with error bars indication s.e.m. p values are determined by unpaired student T-test (<bold>A–E</bold>) or one-way ANOVA Tukey’s multiple comparison test (<bold>D, B</bold>). * p&lt;0.05, **p&lt;0.01, ***p&lt;0.001. n.s.: not significant; n.d: not detected.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96790-fig5-v1.tif"/></fig></sec><sec id="s2-11"><title><italic>The HAQ</italic> allele increased, and the <italic>AQ</italic> allele restored T-regs in <italic>SAVI(N153S</italic>) mice</title><p>IFNγ was proposed to drive SAVI disease (<xref ref-type="bibr" rid="bib59">Stinson et al., 2022</xref>; <xref ref-type="bibr" rid="bib12">Gao et al., 2022</xref>; <xref ref-type="bibr" rid="bib49">Patel and Jin, 2019</xref>). We confirmed that <italic>WT/SAVI</italic> CD4 T cells were enriched with IFNγ<sup>+</sup> cells (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). However, <italic>WT/SAVI</italic> mice have CD4 T cellpenia. Thus, the total numbers of spleen IFNγ<sup>+</sup> CD4 T cells were comparable in <italic>WT/SAVI</italic> and <italic>AQ/SAVI</italic> mice (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). In contrast, the <italic>HAQ/SAVI mice</italic> had decreased IFNγ<sup>+</sup> CD4 T cells (<xref ref-type="fig" rid="fig6">Figure 6A</xref>).</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title><italic>HAQ/SAVI(N153S</italic>) and <italic>AQ/SAVI(N153S</italic>) cells had 10-fold and 20-fold increased spleen T-regs compared to <italic>WT/SAVI</italic> mice.</title><p>(<bold>A</bold>) Flow cytometry analysis of IFNγ producing spleen CD4<sup>+</sup> T cells from <italic>WT/HAQ, WT/AQ, WT/SAVI, HAQ/SAVI</italic> and <italic>AQ/SAVI</italic> mice. (<bold>B</bold>) Flow cytometry analysis of CD4<sup>+</sup> FoxP3<sup>+</sup> spleen T-regs. n=3–5 mice/group. Data are representative of three independent experiments. Graphs represent the mean with error bars indication s.e.m. p values are determined by one-way ANOVA Tukey’s multiple comparison test. * p&lt;0.05, **p&lt;0.01, ***p&lt;0.001. n.s.: not significant.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96790-fig6-v1.tif"/></fig><p>The induction of Foxp3 expression in T-reg cells during ongoing autoimmune inflammation resolved inflammation and pathology in mice (<xref ref-type="bibr" rid="bib20">Hu et al., 2021</xref>). CD4 T cellpenia depletes CD4 T-regs. Indeed, <italic>WT/SAVI</italic> mice had ~20-fold reduction of spleen FoxP3<sup>+</sup> T-regs compared to <italic>AQ/SAVI</italic> or <italic>WT/WT</italic> littermates (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). The <italic>HAQ/SAVI</italic> mice also had ~10-fold more T-regs than the <italic>WT/SAVI</italic> littermate (<xref ref-type="fig" rid="fig6">Figure 6B</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>This study, using the <italic>HAQ, AQ, SAVI(N153S) Sting1</italic> knock-in mice, reveals the in vivo significance and mechanism of STING1-mediated CD4 T cell death. <italic>HAQ, AQ</italic> alleles prevent CD4 T cellpenia, and increase/restore CD4 T-regs in SAVI mice. The results are consistent with previous finding that the impaired CD4 T cell proliferation by the <italic>SAVI(V155M</italic>) mutant could be rescued by the addition of the <italic>HAQ</italic> allele in vitro (<xref ref-type="bibr" rid="bib6">Cerboni et al., 2017</xref>). STING1 has been increasingly implicated in inflammatory diseases such as nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, cardiomyopathy, obesity, diabetes, neurodegenerative diseases, aging, and kidney injury, many of which are independent of type I IFNs (<xref ref-type="bibr" rid="bib57">Skopelja-Gardner et al., 2022</xref>; <xref ref-type="bibr" rid="bib2">Bai and Liu, 2021</xref>; <xref ref-type="bibr" rid="bib13">Gao et al., 2023a</xref>). It is tempting to suggest that STING1 activation in CD4 T cells leads to CD4 T-regs depletion that break tissue tolerance and exacerbates tissue inflammation.</p><p>Human immunodeficiency virus (HIV) primarily infects CD4 T cells and might activate the STING1 pathway in CD4 T cells (<xref ref-type="bibr" rid="bib41">Monroe et al., 2014</xref>; <xref ref-type="bibr" rid="bib9">Doitsh et al., 2014</xref>; <xref ref-type="bibr" rid="bib21">Jakobsen et al., 2015</xref>; <xref ref-type="bibr" rid="bib56">Silvin and Manel, 2015</xref>; <xref ref-type="bibr" rid="bib1">Altfeld and Gale, 2015</xref>; <xref ref-type="bibr" rid="bib27">Krapp et al., 2018</xref>). The loss of CD4 T cells is the hallmark of untreated HIV infection <xref ref-type="bibr" rid="bib16">Gubser et al., 2019</xref>; <xref ref-type="bibr" rid="bib42">Morou et al., 2019</xref>, and the measurement of CD4 T cell count is a central part of HIV care. We found that <italic>HAQ</italic> and <italic>AQ</italic> CD4 T cells are resistant to STING1-mediated cell death. Mogensen and colleagues reported that <italic>HAQ/HAQ</italic> was enriched in HIV-infected long-term nonprogressors (<xref ref-type="bibr" rid="bib46">Nissen et al., 2018</xref>). These <italic>HAQ/HAQ</italic> individuals had reduced inhibition of CD4 T cell proliferation and a reduced immune response to DNA and HIV (<xref ref-type="bibr" rid="bib46">Nissen et al., 2018</xref>). It is likely that HIV infection activates STING1-cell death pathway in CD4 T cells. In <italic>HAQ/SAVI</italic> and <italic>AQ/SAVI</italic> mice, one copy of <italic>HAQ</italic>, <italic>AQ</italic> allele suppressed CD4 T cell death. <italic>HAQ</italic>, <italic>AQ</italic> carriers might have fewer HIV-induced CD4 T cell death, thus being long-term nonprogressors in HIV infection-induced Acquired immunodeficiency syndrome (AIDS; <xref ref-type="bibr" rid="bib46">Nissen et al., 2018</xref>). Targeting STING1 to prevent CD4 T cell death might be a valid therapy for AIDS.</p><p>Activating the STING1 pathway is a promising strategy for cancer immunotherapy (<xref ref-type="bibr" rid="bib19">Hines et al., 2023</xref>; <xref ref-type="bibr" rid="bib54">Samson and Ablasser, 2022</xref>; <xref ref-type="bibr" rid="bib34">Liu et al., 2021</xref>; <xref ref-type="bibr" rid="bib71">Zheng et al., 2020</xref>; <xref ref-type="bibr" rid="bib7">Corrales et al., 2015</xref>; <xref ref-type="bibr" rid="bib11">Fu et al., 2015</xref>; <xref ref-type="bibr" rid="bib3">Barber, 2011</xref>). Multiple STING1 agonists are in clinical trials (<xref ref-type="bibr" rid="bib39">Meric-Bernstam et al., 2023</xref>; <xref ref-type="bibr" rid="bib38">Meric-Bernstam et al., 2022</xref>). Recently, the safety issue emerged in some STING1 agonist trials (<xref ref-type="bibr" rid="bib39">Meric-Bernstam et al., 2023</xref>; <xref ref-type="bibr" rid="bib38">Meric-Bernstam et al., 2022</xref>). For example, in the STING1 agonist, ADU-S100, clinical trial, Grade 3/4 treatment-related adverse events were reported in 12.2% of 41 pretreated patients (NCT02675439) (<xref ref-type="bibr" rid="bib39">Meric-Bernstam et al., 2023</xref>; <xref ref-type="bibr" rid="bib38">Meric-Bernstam et al., 2022</xref>). The National Institutes of Health defines grade 3 as ‘incapacitating; unable to perform usual activities; requires absenteeism or bed rest.’ In a clinical trial using STING1 antibody-drug-conjugate (ADC) that conjugates diABZI to anti-HER2 Ab, a Grade 5 (fatal) serious adverse event was recorded and deemed related to the STING1-ADC (NCT05514717). SAVI disease, driven by overreacting STING1, is often fatal <xref ref-type="bibr" rid="bib32">Liu et al., 2014</xref>. <italic>AQ</italic>, to a less degree, <italic>HAQ</italic>, suppress mortality in SAVI mice. Future STING1 clinical trials should be based on human <italic>STING1</italic> genotype to achieve safe and effective responses.</p><p>Mechanistically, apoptosis, pyroptosis, ferroptosis, necroptosis, and PANoptosis have all been reported in STING1-mediated cell death (<xref ref-type="bibr" rid="bib28">Kuhl et al., 2023</xref>; <xref ref-type="bibr" rid="bib22">Jin et al., 2008</xref>; <xref ref-type="bibr" rid="bib17">Gulen et al., 2017</xref>; <xref ref-type="bibr" rid="bib25">Kabelitz et al., 2022</xref>; <xref ref-type="bibr" rid="bib45">Murthy et al., 2020</xref>; <xref ref-type="bibr" rid="bib30">Li et al., 2021</xref>; <xref ref-type="bibr" rid="bib58">Song et al., 2022</xref>; <xref ref-type="bibr" rid="bib40">Messaoud-Nacer et al., 2022</xref>; <xref ref-type="bibr" rid="bib61">Tang et al., 2016</xref>). Different cell types and STING1 agonists used likely contributed to the inconsistency and complexity. Here, we focused on lymphopenia in the SAVI mice that avoids ligand-dependent, non-physiological dosage in STING1-mediated cell death. <italic>HAQ</italic> and <italic>AQ</italic> alleles could prevent CD4 T cellpenia in the SAVI mice strongly indicating that residue A230 or Q293 prevent STING1-mediated CD4 T cell death in vivo. Splenocyte from <italic>Q293</italic> mice were resistant to STING1 agonists-induced cell death ex vivo. Thus, it is likely that the Q293 residue is critical for STING1-mediate lymphopenia. Notably, Q293 is outside the C-terminal tail (CTT) (residues 341–379 of human STING1) critical for TBK1 recruitment and IRF3 phosphorylation (<xref ref-type="bibr" rid="bib33">Liu et al., 2015</xref>) or miniCTT domain (aa343–354) (<xref ref-type="bibr" rid="bib6">Cerboni et al., 2017</xref>), or the UPR motif (aa322–343) (<xref ref-type="bibr" rid="bib66">Wu et al., 2019</xref>) important for T cells death in vitro. Further studies are needed to understand how the aa293 of STING1 mediates cell death in vivo. Noteworthy, <italic>AQ/SAVI</italic> cells had similar TBK1-IRF3, NFκB activation and STING1 degradation as the <italic>WT/SAVI</italic> cells. Yet, <italic>AQ/SAVI</italic> mice did not have CD4 T cellpenia as <italic>WT/SAVI</italic> mice suggeSting1 that the canonical STING1-TBK1-IRF3/NFκB pathway, likely STING1 oligomerization, is not sufficient for the induction of cell death at the physiological condition.</p><p>We used the <italic>WT/N153S</italic> knock-in SAVI mouse model that spontaneously develop lung inflammation, T cell cytopenia, and early mortality, mimicking pathological findings in human SAVI patients (<xref ref-type="bibr" rid="bib65">Warner et al., 2017</xref>). Using the <italic>WT/N153S</italic> SAVI mouse model and human Jurkat T cell line, it was proposed that STING1 activation causes chronic ER stress and unfolded protein response, leading to T cell death by apoptosis (<xref ref-type="bibr" rid="bib66">Wu et al., 2019</xref>). Furthermore, the study showed that crossing <italic>WT/N153S</italic> mice to the OT-I mice reduced ER stress and restored CD8<sup>+</sup>, but not CD4<sup>+</sup>, T cells (<xref ref-type="bibr" rid="bib66">Wu et al., 2019</xref>). The restoration of CD8<sup>+</sup>T cells reduces inflammation and lung disease (<xref ref-type="bibr" rid="bib66">Wu et al., 2019</xref>). However, human <italic>WT/N154S</italic> SAVI patients have normal CD8<sup>+</sup> T cells numbers (<xref ref-type="bibr" rid="bib32">Liu et al., 2014</xref>), and primary human CD8<sup>+</sup> T cells are largely resistant to STING1-agonists-induced cell death ex vivo (<xref ref-type="fig" rid="fig2">Figure 2A</xref>; <xref ref-type="bibr" rid="bib28">Kuhl et al., 2023</xref>). Thus, it is puzzling how restoring CD8<sup>+</sup> T cells can rescue SAVI phenotypes since the SAVI patients already have normal CD8<sup>+</sup> T cells numbers.</p><p>Finally, it is unexpected that both <italic>HAQ</italic> and <italic>AQ</italic> alleles are resistant to cell death. Our previous studies showed that the <italic>HAQ</italic> and <italic>AQ</italic> alleles have opposite functions (<xref ref-type="bibr" rid="bib37">Mansouri et al., 2022</xref>). AQ-STING1, not HAQ-STING1, responds to CDNs (<xref ref-type="bibr" rid="bib23">Jin et al., 2011</xref>; <xref ref-type="bibr" rid="bib47">Patel et al., 2017a</xref>; <xref ref-type="bibr" rid="bib37">Mansouri et al., 2022</xref>; <xref ref-type="bibr" rid="bib55">Sebastian et al., 2020</xref>; <xref ref-type="bibr" rid="bib70">Yi et al., 2013</xref>; <xref ref-type="bibr" rid="bib48">Patel et al., 2017b</xref>; <xref ref-type="bibr" rid="bib46">Nissen et al., 2018</xref>; <xref ref-type="bibr" rid="bib53">Ruiz-Moreno et al., 2018</xref>; <xref ref-type="bibr" rid="bib44">Movert et al., 2023</xref>). <italic>AQ</italic> mice are lean while <italic>HAQ</italic> mice are fat (<xref ref-type="bibr" rid="bib37">Mansouri et al., 2022</xref>). Most importantly, <italic>HAQ</italic> was positively selected, while <italic>AQ</italic> was negatively selected, in modern humans outside Africans (<xref ref-type="bibr" rid="bib37">Mansouri et al., 2022</xref>). Thus, the death pathway of STING1 is also distinct from the STING1 function that was naturally selected. It is worth noting that the <italic>AQ</italic> allele does better than the <italic>HAQ</italic> allele in suppressing SAVI disease. Thus, besides preventing cell death, additional mechanism by the <italic>AQ</italic> allele, for example fatty acid metabolism (<xref ref-type="bibr" rid="bib37">Mansouri et al., 2022</xref>; <xref ref-type="bibr" rid="bib63">Vila et al., 2022</xref>), is involved in curing SAVI.</p><sec id="s3-1"><title>The limitations of the study</title><p>The poor transferability of mouse to humans is a major issue in STING1 research (<xref ref-type="bibr" rid="bib39">Meric-Bernstam et al., 2023</xref>; <xref ref-type="bibr" rid="bib38">Meric-Bernstam et al., 2022</xref>). The present study used <italic>AQ/SAVI</italic> and <italic>HAQ/SAVI</italic> mice. Confirmation is needed in humans with the identification and evaluation of people who are <italic>AQ/SAVI</italic>, <italic>HAQ/SAVI</italic>.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Experimental design</title><p>The study was designed to reveal (i) the in vivo significance of the type I IFNs-independent, STING1-dependent cell death function; (ii) the interplay between common <italic>STING1</italic> alleles <italic>HAQ, AQ</italic> and the rare, gain-of-function SAVI STING1 mutation; (iii) the driver for the inflammatory SAVI disease. Mouse splenocytes, primary human lung cells, human THP-1 cells and <italic>HAQ, AQ, SAVI</italic> knock-in mice were used to establish the in vivo significance and human relevance. All the repeats were biological replications that involve the same experimental procedures on different mice. Where possible, treatments were assigned blindly to the experimenter by another individual in the lab. When comparing samples from different groups, samples from each group were analyzed in concert, thereby preventing any biases that might arise from analyzing individual treatments on different days. All experiments were repeated at least twice.</p></sec><sec id="s4-2"><title>Mice</title><p><italic>WT/SAVI(N153S</italic>) mice were purchased from The Jackson Laboratory. <italic>HAQ</italic>, <italic>AQ</italic> mice were previously generated in the lab (<xref ref-type="bibr" rid="bib47">Patel et al., 2017a</xref>; <xref ref-type="bibr" rid="bib37">Mansouri et al., 2022</xref>). The <italic>Q293</italic> mice were generated by Cyagen Biosciences. Briefly, the linearized targeting vector was transfected into JM8A3.N1 C57BL/6 N embryonic stem cells. A positive embryonic stem clone was subjected to the generation of chimera mice by injection using C57BL/6 J blastocysts as the host. Successful germline transmission was confirmed by PCR sequencing. The heterozygous mice were bred to Actin-flpase mice [The Jackson Laboratory, B6.Cg-Tg (ACTFLPe)9205Dym/J] to remove the neo gene and make the <italic>Q293</italic> knock-in mouse. Age- and gender-matched mice (2–6 month old, both male and female) were used for indicated experiments. <italic>WT/SAVI</italic> (male) x <italic>WT/HAQ</italic> (female), <italic>WT/SAVI</italic> (male) x <italic>WT/AQ</italic> (female) breeders were set up to generate <italic>HAQ/SAVI</italic>, <italic>AQ/SAVI</italic> mice. Mice were housed at 22 °C under a 12‐hr light‐dark cycle with ad libitum access to water and a chow diet (3.1 kcal/g, Teklad 2018, Envigo, Sommerset, NJ) and bred under pathogen-free conditions in the Animal Research Facility at the University of Florida. Littermates of the same sex were randomly assigned to experimental groups. All mouse experiments were performed by the regulations and approval of the Institutional Animal Care and Use Committee at the University of Florida, IACUC202200000058.</p></sec><sec id="s4-3"><title>Reagent</title><p>Recombinant human IFNβ (R&amp;D, cat no. 8499-IF-010/CF), diABZI (Invivogen, cat no. 2138299-34-8), 2’3’-cGAMP (Invivogen, cat no. tlrl-nacga23-02), DMXAA (Invivogen, cat no. tlrl-dmx), H151 (Invivogen, cat no. inh-h151), RpRpSS-Cyclic di-AMP (Biolog, cat no. C118), THP1-Dual KO-STING1 Cells (Invivogen, cat no. thpd-kostg). All other chemical inhibitors are from Selleckchem. Mouse TNF alpha ELISA Ready Set Go. (eBioscience, cat no. 88–7324). Mouse IFN-Beta ELISA Kit (PBI, cat no. 42400).</p></sec><sec id="s4-4"><title>Generation of THP-1 KO-STING1 cells stably expressing human <italic>STING1</italic> alleles</title><p>THP1-Dual KO-STING1 cells were purchased from Invivogen (thpd-kostg). These cells are guaranteed mycoplasma-free and authenticated by the vendor. THP1-Dual KO-STING1 Cells in six-well plate were transfected with 1 µg <italic>STING1</italic> plasmid (in pcDNA 3.1 vector) with Lipofectamine LTX and Plus Reagent (Invitrogen, cat no: A12621) according to the manufacturer’s instructions.<ext-link ext-link-type="uri" xlink:href="https://www.thermofisher.com/us/en/home/references/protocols/cell-culture/transfection-protocol/transfecting-plasmid-dna-into-thp-1-cells-using-lipofectamine-ltx-reagent.html#1"> Transfecting Plasmid DNA into THP-1 Cells Using Lipofectamine LTX Reagent | Thermo Fisher Scientific - US</ext-link>. Forty-eight hours after the transfection, the cell medium was changed. G418 (1 mg/ml) was added to the culture to select STING1 expressing THP-1 cells. The G418-resistant cells were established and expanded.</p></sec><sec id="s4-5"><title>Histology</title><p>Lungs and livers were fixed in 10% formalin, paraffin-embedded, and cut into 4 µm sections. Lung, liver sections were then stained for hematoxylin-eosin. All staining procedures were performed by the histology core at the University of Florida. Briefly, tissue sectins were immersed Harris Hematoxylin for 10 s, then washed with tap water. Cleard sections were re-immersed in EOSIN stain for ~30 s. The sections were washed with tap water until clear, then dehydrate in ascending alcohol solutions (50%, 70%, 80%, 95% x 2, 100% x 2). Afterwards, the sections werer cleared with xylene (3–4 x). The sections were mounted on glass slide with permount organic mounting medium for visulization.</p></sec><sec id="s4-6"><title>Lung function</title><p>Pulmonary function was evaluated using an isolated, buffer-perfused mouse lung apparatus (Hugo Sachs Elektronik, March-Huggstetten, Germany), as previously described (<xref ref-type="bibr" rid="bib5">Cai et al., 2020</xref>). Briefly, mice were anesthetized with ketamine and xylazine and a tracheostomy was performed, and animals were ventilated with room air at 100 breaths/min at a tidal volume of 7 μl/g body weight with a positive end-expiratory pressure of 2 cm H<sub>2</sub>O using a pressure-controlled ventilator (Hugo Sachs Elektronik, March-Huggstetten, Germany).</p></sec><sec id="s4-7"><title>Isolation of lung cells</title><p>Cells were isolated from the lung as previously described (<xref ref-type="bibr" rid="bib36">Mansouri et al., 2020</xref>). The lungs were perfused with ice-cold PBS and removed. Lungs were digested in DMEM containing 200 μg/ml DNase I (Roche, 10104159001), 25 μg/ml Liberase TM (Roche, 05401119001) at 37 °C for 2 hr. Red blood cells were then lysed and a single-cell suspension was prepared by filtering through a 70 µm cell strainer.</p></sec><sec id="s4-8"><title>BMDM activation</title><p>BMDMs were induced from mouse bone marrow cells cultured in RPMI 1640 (cat#11965; Invitrogen) with 10% FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, 10 mM HEPES buffer, 1% nonessential amino acids, 50 mM 2-ME, 1% Pen/Strep, with 20 ng/ml M-CSF (Kingfisher, RP0407M) for 10 days (<xref ref-type="bibr" rid="bib47">Patel et al., 2017a</xref>). STING1 agonists were added into the culture (no transfection or membrane permeabilization).</p></sec><sec id="s4-9"><title>Flow cytometry</title><p>Single-cell suspensions were stained with fluorescent-dye-conjugated antibodies in PBS containing 2% FBS and 1 mM EDTA. Surface stains were performed at 4 °C for 20 min. For intracellular cytokine or transcription factor staining of murine and human cells, cells were fixed and permeabilized with the Foxp3 staining buffer set (eBioscience, cat no 00-5523-00). Cells were washed and stained with surface markers. Cells were then fixed and permeabilized (eBioscience, cat no. 00-5523-00) for intracellular cytokine stain. Data were acquired on a BD LSRFortessa and analyzed using the FlowJo software package (FlowJo, LLC). Cell sorting was performed on the BD FACSAriaIII Flow Cytometer and Cell Sorter.</p></sec><sec id="s4-10"><title>Human lung explants</title><p>Human lung explants were procured at the Lung Transplant Center, Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Florida. Donor and patients consent was obtained for a research protocol (UF IRB201902955-Treatment with IFNβ Induces Tolerogenic Lung Dendritic Cells in Human advanced lung disease). Healthy donor lungs were surgically removed postmortem, perfused, small pieces were cut from the right middle and lower lobes for research purpose, and stored in cold Perfadex at 4 °C for no more than 12 hr before processing. Ex planted lungs from emphysema lung transplant patients were stored in cold Perfadex at 4 °C for no more than 12 hr before the process. No lung explants were procured from prisoners.</p></sec><sec id="s4-11"><title>Statistical analysis</title><p>To gain statistical power, we employ three ~four mice/groups to characterize lung immunity. Ten mice/group to monitor animal health. The statistical justification for group size was calculated using the SAS program to calculate the animal numbers. The analysis was carried out using a standard error of 0.5 for immunological assays, and a power of 0.9. All data are expressed as means ± SEM. Statistical significance was evaluated using Prism 9.0 software. Comparisons between two groups were analyzed by performing an unpaired Student’s <italic>t</italic> test. Comparisons between more than two groups were analyzed by performing a one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test.</p></sec><sec id="s4-12"><title>Materials availability statement</title><p>The Q293 mouse is available upon request via a Material Transfer Agreement.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Resources, Methodology</p></fn><fn fn-type="con" id="con5"><p>Data curation, Formal analysis, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Data curation, Formal analysis, Supervision, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Methodology, Writing - original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>The donor lung and data are from deceased individuals. The specimens or data are de-identified for the purpose of this study. Under these conditions, the human study is exempt from Federal regulation, under category 4 (E4) Human lung explants were procured at the Lung Transplant Center, Division of Pulmonary,Critical Care and Sleep Medicine, Department of Medicine, University of Florida. Donor and patients consent was obtained for a research protocol (UF IRB201902955-Treatment with IFNs; Induces Tolerogenic Lung Dendritic Cells in Human advanced lung disease).</p></fn><fn fn-type="other"><p>All mouse experiments were performed by the regulations and approval of the Institutional Animal Care and Use Committee at the University of Florida, IACUC202200000058.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-96790-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Source data is deposited in Dryad <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5061/dryad.m0cfxppcv">https://doi.org/10.5061/dryad.m0cfxppcv</ext-link>.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Data from: The common TMEM173 HAQ, AQ alleles rescue CD4 T cellpenia, restore T-regs, and prevent SAVI (N153S) inflammatory disease in mice</data-title><source>Dryad Digital Repository</source><pub-id pub-id-type="doi">10.5061/dryad.m0cfxppcv</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>National Institutes of Health grant HL152163 (LJ).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altfeld</surname><given-names>M</given-names></name><name><surname>Gale</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Innate immunity against HIV-1 infection</article-title><source>Nature Immunology</source><volume>16</volume><fpage>554</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1038/ni.3157</pub-id><pub-id pub-id-type="pmid">25988887</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>cGAS‒STING signaling and function in metabolism and kidney diseases</article-title><source>Journal of Molecular Cell Biology</source><volume>13</volume><fpage>728</fpage><lpage>738</lpage><pub-id pub-id-type="doi">10.1093/jmcb/mjab066</pub-id><pub-id pub-id-type="pmid">34665236</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barber</surname><given-names>GN</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Innate immune DNA sensing pathways: STING, AIMII and the regulation of interferon production and inflammatory responses</article-title><source>Current Opinion in Immunology</source><volume>23</volume><fpage>10</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2010.12.015</pub-id><pub-id pub-id-type="pmid">21239155</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barber</surname><given-names>GN</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>STING: infection, inflammation and cancer</article-title><source>Nature Reviews. Immunology</source><volume>15</volume><fpage>760</fpage><lpage>770</lpage><pub-id pub-id-type="doi">10.1038/nri3921</pub-id><pub-id pub-id-type="pmid">26603901</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>J</given-names></name><name><surname>Gehrau</surname><given-names>R</given-names></name><name><surname>Tu</surname><given-names>Z</given-names></name><name><surname>Leroy</surname><given-names>V</given-names></name><name><surname>Su</surname><given-names>G</given-names></name><name><surname>Shang</surname><given-names>J</given-names></name><name><surname>Mas</surname><given-names>VR</given-names></name><name><surname>Emtiazjoo</surname><given-names>A</given-names></name><name><surname>Pelaez</surname><given-names>A</given-names></name><name><surname>Atkinson</surname><given-names>C</given-names></name><name><surname>Machuca</surname><given-names>T</given-names></name><name><surname>Upchurch</surname><given-names>GR</given-names></name><name><surname>Sharma</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>MicroRNA-206 antagomiR‒enriched extracellular vesicles attenuate lung ischemia‒reperfusion injury through CXCL1 regulation in alveolar epithelial cells</article-title><source>The Journal of Heart and Lung Transplantation</source><volume>39</volume><fpage>1476</fpage><lpage>1490</lpage><pub-id pub-id-type="doi">10.1016/j.healun.2020.09.012</pub-id><pub-id pub-id-type="pmid">33067103</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerboni</surname><given-names>S</given-names></name><name><surname>Jeremiah</surname><given-names>N</given-names></name><name><surname>Gentili</surname><given-names>M</given-names></name><name><surname>Gehrmann</surname><given-names>U</given-names></name><name><surname>Conrad</surname><given-names>C</given-names></name><name><surname>Stolzenberg</surname><given-names>MC</given-names></name><name><surname>Picard</surname><given-names>C</given-names></name><name><surname>Neven</surname><given-names>B</given-names></name><name><surname>Fischer</surname><given-names>A</given-names></name><name><surname>Amigorena</surname><given-names>S</given-names></name><name><surname>Rieux-Laucat</surname><given-names>F</given-names></name><name><surname>Manel</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Intrinsic antiproliferative activity of the innate sensor STING in T lymphocytes</article-title><source>The Journal of Experimental Medicine</source><volume>214</volume><fpage>1769</fpage><lpage>1785</lpage><pub-id pub-id-type="doi">10.1084/jem.20161674</pub-id><pub-id pub-id-type="pmid">28484079</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corrales</surname><given-names>L</given-names></name><name><surname>Glickman</surname><given-names>LH</given-names></name><name><surname>McWhirter</surname><given-names>SM</given-names></name><name><surname>Kanne</surname><given-names>DB</given-names></name><name><surname>Sivick</surname><given-names>KE</given-names></name><name><surname>Katibah</surname><given-names>GE</given-names></name><name><surname>Woo</surname><given-names>SR</given-names></name><name><surname>Lemmens</surname><given-names>E</given-names></name><name><surname>Banda</surname><given-names>T</given-names></name><name><surname>Leong</surname><given-names>JJ</given-names></name><name><surname>Metchette</surname><given-names>K</given-names></name><name><surname>Dubensky</surname><given-names>TW</given-names></name><name><surname>Gajewski</surname><given-names>TF</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Direct Activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity</article-title><source>Cell Reports</source><volume>11</volume><fpage>1018</fpage><lpage>1030</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.04.031</pub-id><pub-id pub-id-type="pmid">25959818</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Yin</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Stimulator of interferon genes-associated vasculopathy with onset in infancy: a systematic review of case reports</article-title><source>Frontiers in Pediatrics</source><volume>8</volume><elocation-id>577918</elocation-id><pub-id pub-id-type="doi">10.3389/fped.2020.577918</pub-id><pub-id pub-id-type="pmid">33425809</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doitsh</surname><given-names>G</given-names></name><name><surname>Galloway</surname><given-names>NLK</given-names></name><name><surname>Geng</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Monroe</surname><given-names>KM</given-names></name><name><surname>Zepeda</surname><given-names>O</given-names></name><name><surname>Hunt</surname><given-names>PW</given-names></name><name><surname>Hatano</surname><given-names>H</given-names></name><name><surname>Sowinski</surname><given-names>S</given-names></name><name><surname>Muñoz-Arias</surname><given-names>I</given-names></name><name><surname>Greene</surname><given-names>WC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection</article-title><source>Nature</source><volume>505</volume><fpage>509</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1038/nature12940</pub-id><pub-id pub-id-type="pmid">24356306</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frémond</surname><given-names>M-L</given-names></name><name><surname>Hadchouel</surname><given-names>A</given-names></name><name><surname>Berteloot</surname><given-names>L</given-names></name><name><surname>Melki</surname><given-names>I</given-names></name><name><surname>Bresson</surname><given-names>V</given-names></name><name><surname>Barnabei</surname><given-names>L</given-names></name><name><surname>Jeremiah</surname><given-names>N</given-names></name><name><surname>Belot</surname><given-names>A</given-names></name><name><surname>Bondet</surname><given-names>V</given-names></name><name><surname>Brocq</surname><given-names>O</given-names></name><name><surname>Chan</surname><given-names>D</given-names></name><name><surname>Dagher</surname><given-names>R</given-names></name><name><surname>Dubus</surname><given-names>J-C</given-names></name><name><surname>Duffy</surname><given-names>D</given-names></name><name><surname>Feuillet-Soummer</surname><given-names>S</given-names></name><name><surname>Fusaro</surname><given-names>M</given-names></name><name><surname>Gattorno</surname><given-names>M</given-names></name><name><surname>Insalaco</surname><given-names>A</given-names></name><name><surname>Jeziorski</surname><given-names>E</given-names></name><name><surname>Kitabayashi</surname><given-names>N</given-names></name><name><surname>Lopez-Corbeto</surname><given-names>M</given-names></name><name><surname>Mazingue</surname><given-names>F</given-names></name><name><surname>Morren</surname><given-names>M-A</given-names></name><name><surname>Rice</surname><given-names>GI</given-names></name><name><surname>Rivière</surname><given-names>JG</given-names></name><name><surname>Seabra</surname><given-names>L</given-names></name><name><surname>Sirvente</surname><given-names>J</given-names></name><name><surname>Soler-Palacin</surname><given-names>P</given-names></name><name><surname>Stremler-Le Bel</surname><given-names>N</given-names></name><name><surname>Thouvenin</surname><given-names>G</given-names></name><name><surname>Thumerelle</surname><given-names>C</given-names></name><name><surname>Van Aerde</surname><given-names>E</given-names></name><name><surname>Volpi</surname><given-names>S</given-names></name><name><surname>Willcocks</surname><given-names>S</given-names></name><name><surname>Wouters</surname><given-names>C</given-names></name><name><surname>Breton</surname><given-names>S</given-names></name><name><surname>Molina</surname><given-names>T</given-names></name><name><surname>Bader-Meunier</surname><given-names>B</given-names></name><name><surname>Moshous</surname><given-names>D</given-names></name><name><surname>Fischer</surname><given-names>A</given-names></name><name><surname>Blanche</surname><given-names>S</given-names></name><name><surname>Rieux-Laucat</surname><given-names>F</given-names></name><name><surname>Crow</surname><given-names>YJ</given-names></name><name><surname>Neven</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Overview of STING-associated vasculopathy with onset in infancy (SAVI) Among 21 Patients</article-title><source>The Journal of Allergy and Clinical Immunology</source><volume>9</volume><fpage>803</fpage><lpage>818</lpage><pub-id pub-id-type="doi">10.1016/j.jaip.2020.11.007</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Kanne</surname><given-names>DB</given-names></name><name><surname>Leong</surname><given-names>M</given-names></name><name><surname>Glickman</surname><given-names>LH</given-names></name><name><surname>McWhirter</surname><given-names>SM</given-names></name><name><surname>Lemmens</surname><given-names>E</given-names></name><name><surname>Mechette</surname><given-names>K</given-names></name><name><surname>Leong</surname><given-names>JJ</given-names></name><name><surname>Lauer</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Sivick</surname><given-names>KE</given-names></name><name><surname>Zeng</surname><given-names>Q</given-names></name><name><surname>Soares</surname><given-names>KC</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Portnoy</surname><given-names>DA</given-names></name><name><surname>Woodward</surname><given-names>JJ</given-names></name><name><surname>Pardoll</surname><given-names>DM</given-names></name><name><surname>Dubensky</surname><given-names>TW</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade</article-title><source>Science Translational Medicine</source><volume>7</volume><elocation-id>283ra252</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aaa4306</pub-id><pub-id pub-id-type="pmid">25877890</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>KM</given-names></name><name><surname>Motwani</surname><given-names>M</given-names></name><name><surname>Tedder</surname><given-names>T</given-names></name><name><surname>Marshak-Rothstein</surname><given-names>A</given-names></name><name><surname>Fitzgerald</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Radioresistant cells initiate lymphocyte-dependent lung inflammation and IFNγ-dependent mortality in STING gain-of-function mice</article-title><source>PNAS</source><volume>119</volume><elocation-id>e2202327119</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2202327119</pub-id><pub-id pub-id-type="pmid">35696583</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>KM</given-names></name><name><surname>Marshak-Rothstein</surname><given-names>A</given-names></name><name><surname>Fitzgerald</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2023">2023a</year><article-title>Type-1 interferon-dependent and -independent mechanisms in cyclic GMP-AMP synthase-stimulator of interferon genes-driven auto-inflammation</article-title><source>Current Opinion in Immunology</source><volume>80</volume><elocation-id>102280</elocation-id><pub-id pub-id-type="doi">10.1016/j.coi.2022.102280</pub-id><pub-id pub-id-type="pmid">36638547</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Gong</surname><given-names>T</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>He</surname><given-names>C</given-names></name><name><surname>Meng</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2023">2023b</year><article-title>STING/ACSL4 axis-dependent ferroptosis and inflammation promote hypertension-associated chronic kidney disease</article-title><source>Molecular Therapy</source><volume>31</volume><fpage>3084</fpage><lpage>3103</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2023.07.026</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>KM</given-names></name><name><surname>Chiang</surname><given-names>K</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Korkmaz</surname><given-names>FT</given-names></name><name><surname>Janardhan</surname><given-names>HP</given-names></name><name><surname>Trivedi</surname><given-names>CM</given-names></name><name><surname>Quinton</surname><given-names>LJ</given-names></name><name><surname>Gingras</surname><given-names>S</given-names></name><name><surname>Fitzgerald</surname><given-names>KA</given-names></name><name><surname>Marshak-Rothstein</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Endothelial cell expression of a STING gain-of-function mutation initiates pulmonary lymphocytic infiltration</article-title><source>Cell Reports</source><volume>43</volume><elocation-id>114114</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2024.114114</pub-id><pub-id pub-id-type="pmid">38625791</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gubser</surname><given-names>C</given-names></name><name><surname>Pitman</surname><given-names>MC</given-names></name><name><surname>Lewin</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>CD4+ T cell signatures in HIV infection</article-title><source>Nature Immunology</source><volume>20</volume><fpage>948</fpage><lpage>950</lpage><pub-id pub-id-type="doi">10.1038/s41590-019-0447-5</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gulen</surname><given-names>MF</given-names></name><name><surname>Koch</surname><given-names>U</given-names></name><name><surname>Haag</surname><given-names>SM</given-names></name><name><surname>Schuler</surname><given-names>F</given-names></name><name><surname>Apetoh</surname><given-names>L</given-names></name><name><surname>Villunger</surname><given-names>A</given-names></name><name><surname>Radtke</surname><given-names>F</given-names></name><name><surname>Ablasser</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Signalling strength determines proapoptotic functions of STING</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>427</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-017-00573-w</pub-id><pub-id pub-id-type="pmid">28874664</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gulen</surname><given-names>MF</given-names></name><name><surname>Samson</surname><given-names>N</given-names></name><name><surname>Keller</surname><given-names>A</given-names></name><name><surname>Schwabenland</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Glück</surname><given-names>S</given-names></name><name><surname>Thacker</surname><given-names>VV</given-names></name><name><surname>Favre</surname><given-names>L</given-names></name><name><surname>Mangeat</surname><given-names>B</given-names></name><name><surname>Kroese</surname><given-names>LJ</given-names></name><name><surname>Krimpenfort</surname><given-names>P</given-names></name><name><surname>Prinz</surname><given-names>M</given-names></name><name><surname>Ablasser</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>cGAS-STING drives ageing-related inflammation and neurodegeneration</article-title><source>Nature</source><volume>620</volume><fpage>374</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06373-1</pub-id><pub-id pub-id-type="pmid">37532932</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hines</surname><given-names>JB</given-names></name><name><surname>Kacew</surname><given-names>AJ</given-names></name><name><surname>Sweis</surname><given-names>RF</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The Development of STING agonists and emerging results as a cancer immunotherapy</article-title><source>Current Oncology Reports</source><volume>25</volume><fpage>189</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1007/s11912-023-01361-0</pub-id><pub-id pub-id-type="pmid">36705879</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>ZM</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Schizas</surname><given-names>M</given-names></name><name><surname>Hoyos</surname><given-names>BE</given-names></name><name><surname>Veeken</surname><given-names>J</given-names></name><name><surname>Verter</surname><given-names>JG</given-names></name><name><surname>Bou-Puerto</surname><given-names>R</given-names></name><name><surname>Rudensky</surname><given-names>AY</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Regulatory T cells function in established systemic inflammation and reverse fatal autoimmunity</article-title><source>Nat Immunol</source><volume>22</volume><fpage>1163</fpage><lpage>1174</lpage></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jakobsen</surname><given-names>MR</given-names></name><name><surname>Olagnier</surname><given-names>D</given-names></name><name><surname>Hiscott</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Innate immune sensing of HIV-1 infection</article-title><source>Current Opinion in HIV and AIDS</source><volume>10</volume><fpage>96</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1097/COH.0000000000000129</pub-id><pub-id pub-id-type="pmid">25485569</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>L</given-names></name><name><surname>Waterman</surname><given-names>PM</given-names></name><name><surname>Jonscher</surname><given-names>KR</given-names></name><name><surname>Short</surname><given-names>CM</given-names></name><name><surname>Reisdorph</surname><given-names>NA</given-names></name><name><surname>Cambier</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>MPYS, a novel membrane tetraspanner, is associated with major histocompatibility complex class II and mediates transduction of apoptotic signals</article-title><source>Molecular and Cellular Biology</source><volume>28</volume><fpage>5014</fpage><lpage>5026</lpage><pub-id pub-id-type="doi">10.1128/MCB.00640-08</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>LG</given-names></name><name><surname>Yang</surname><given-names>IV</given-names></name><name><surname>Davidson</surname><given-names>EJ</given-names></name><name><surname>Schwartz</surname><given-names>DA</given-names></name><name><surname>Wurfel</surname><given-names>MM</given-names></name><name><surname>Cambier</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Identification and characterization of a loss-of-function human MPYS variant</article-title><source>Genes and Immunity</source><volume>12</volume><fpage>263</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1038/gene.2010.75</pub-id><pub-id pub-id-type="pmid">21248775</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>L</given-names></name><name><surname>Getahun</surname><given-names>A</given-names></name><name><surname>Knowles</surname><given-names>HM</given-names></name><name><surname>Mogan</surname><given-names>J</given-names></name><name><surname>Akerlund</surname><given-names>LJ</given-names></name><name><surname>Packard</surname><given-names>TA</given-names></name><name><surname>Perraud</surname><given-names>AL</given-names></name><name><surname>Cambier</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>STING/MPYS mediates host defense against Listeria monocytogenes infection by regulating Ly6C(hi) monocyte migration</article-title><source>Journal of Immunology</source><volume>190</volume><fpage>2835</fpage><lpage>2843</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1201788</pub-id><pub-id pub-id-type="pmid">23378430</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kabelitz</surname><given-names>D</given-names></name><name><surname>Zarobkiewicz</surname><given-names>M</given-names></name><name><surname>Heib</surname><given-names>M</given-names></name><name><surname>Serrano</surname><given-names>R</given-names></name><name><surname>Kunz</surname><given-names>M</given-names></name><name><surname>Chitadze</surname><given-names>G</given-names></name><name><surname>Adam</surname><given-names>D</given-names></name><name><surname>Peters</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Signal strength of STING activation determines cytokine plasticity and cell death in human monocytes</article-title><source>Scientific Reports</source><volume>12</volume><elocation-id>17827</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-022-20519-7</pub-id><pub-id pub-id-type="pmid">36280676</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Song</surname><given-names>KB</given-names></name><name><surname>Choi</surname><given-names>EJ</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>A 17-year-old girl diagnosed with sting-associated vasculopathy with onset in infancy (SAVI) after lung transplantation</article-title><source>Chest</source><volume>162</volume><fpage>e249</fpage><lpage>e252</lpage><pub-id pub-id-type="doi">10.1016/j.chest.2022.05.025</pub-id><pub-id pub-id-type="pmid">36344133</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krapp</surname><given-names>C</given-names></name><name><surname>Jønsson</surname><given-names>K</given-names></name><name><surname>Jakobsen</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>STING dependent sensing - Does HIV actually care?</article-title><source>Cytokine &amp; Growth Factor Reviews</source><volume>40</volume><fpage>68</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2018.03.002</pub-id><pub-id pub-id-type="pmid">29548644</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhl</surname><given-names>N</given-names></name><name><surname>Linder</surname><given-names>A</given-names></name><name><surname>Philipp</surname><given-names>N</given-names></name><name><surname>Nixdorf</surname><given-names>D</given-names></name><name><surname>Fischer</surname><given-names>H</given-names></name><name><surname>Veth</surname><given-names>S</given-names></name><name><surname>Kuut</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>TT</given-names></name><name><surname>Theurich</surname><given-names>S</given-names></name><name><surname>Carell</surname><given-names>T</given-names></name><name><surname>Subklewe</surname><given-names>M</given-names></name><name><surname>Hornung</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>STING agonism turns human T cells into interferon-producing cells but impedes their functionality</article-title><source>EMBO Reports</source><volume>24</volume><elocation-id>e55536</elocation-id><pub-id pub-id-type="doi">10.15252/embr.202255536</pub-id><pub-id pub-id-type="pmid">36705069</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larkin</surname><given-names>B</given-names></name><name><surname>Ilyukha</surname><given-names>V</given-names></name><name><surname>Sorokin</surname><given-names>M</given-names></name><name><surname>Buzdin</surname><given-names>A</given-names></name><name><surname>Vannier</surname><given-names>E</given-names></name><name><surname>Poltorak</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cutting edge: activation of STING in T cells induces type I IFN responses and cell death</article-title><source>Journal of Immunology</source><volume>199</volume><fpage>397</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1601999</pub-id><pub-id pub-id-type="pmid">28615418</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Hou</surname><given-names>W</given-names></name><name><surname>Kang</surname><given-names>R</given-names></name><name><surname>Tang</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>STING1 promotes ferroptosis through MFN1/2-dependent mitochondrial fusion</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>9</volume><elocation-id>698679</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2021.698679</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Aquino</surname><given-names>E</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Mini review: STING activation during non-alcoholic fatty liver disease</article-title><source>Frontiers in Nutrition</source><volume>10</volume><elocation-id>1139339</elocation-id><pub-id pub-id-type="doi">10.3389/fnut.2023.1139339</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Jesus</surname><given-names>AA</given-names></name><name><surname>Marrero</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Ramsey</surname><given-names>SE</given-names></name><name><surname>Montealegre Sanchez</surname><given-names>GA</given-names></name><name><surname>Tenbrock</surname><given-names>K</given-names></name><name><surname>Wittkowski</surname><given-names>H</given-names></name><name><surname>Jones</surname><given-names>OY</given-names></name><name><surname>Kuehn</surname><given-names>HS</given-names></name><name><surname>Lee</surname><given-names>C-CR</given-names></name><name><surname>DiMattia</surname><given-names>MA</given-names></name><name><surname>Cowen</surname><given-names>EW</given-names></name><name><surname>Gonzalez</surname><given-names>B</given-names></name><name><surname>Palmer</surname><given-names>I</given-names></name><name><surname>DiGiovanna</surname><given-names>JJ</given-names></name><name><surname>Biancotto</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Tsai</surname><given-names>WL</given-names></name><name><surname>Trier</surname><given-names>AM</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Stone</surname><given-names>DL</given-names></name><name><surname>Hill</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>St. Hilaire</surname><given-names>C</given-names></name><name><surname>Gurprasad</surname><given-names>S</given-names></name><name><surname>Plass</surname><given-names>N</given-names></name><name><surname>Chapelle</surname><given-names>D</given-names></name><name><surname>Horkayne-Szakaly</surname><given-names>I</given-names></name><name><surname>Foell</surname><given-names>D</given-names></name><name><surname>Barysenka</surname><given-names>A</given-names></name><name><surname>Candotti</surname><given-names>F</given-names></name><name><surname>Holland</surname><given-names>SM</given-names></name><name><surname>Hughes</surname><given-names>JD</given-names></name><name><surname>Mehmet</surname><given-names>H</given-names></name><name><surname>Issekutz</surname><given-names>AC</given-names></name><name><surname>Raffeld</surname><given-names>M</given-names></name><name><surname>McElwee</surname><given-names>J</given-names></name><name><surname>Fontana</surname><given-names>JR</given-names></name><name><surname>Minniti</surname><given-names>CP</given-names></name><name><surname>Moir</surname><given-names>S</given-names></name><name><surname>Kastner</surname><given-names>DL</given-names></name><name><surname>Gadina</surname><given-names>M</given-names></name><name><surname>Steven</surname><given-names>AC</given-names></name><name><surname>Wingfield</surname><given-names>PT</given-names></name><name><surname>Brooks</surname><given-names>SR</given-names></name><name><surname>Rosenzweig</surname><given-names>SD</given-names></name><name><surname>Fleisher</surname><given-names>TA</given-names></name><name><surname>Deng</surname><given-names>Z</given-names></name><name><surname>Boehm</surname><given-names>M</given-names></name><name><surname>Paller</surname><given-names>AS</given-names></name><name><surname>Goldbach-Mansky</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Activated STING in a vascular and pulmonary syndrome</article-title><source>New England Journal of Medicine</source><volume>371</volume><fpage>507</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1312625</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Cai</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Cong</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Du</surname><given-names>F</given-names></name><name><surname>Ren</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>YT</given-names></name><name><surname>Grishin</surname><given-names>NV</given-names></name><name><surname>Chen</surname><given-names>ZJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation</article-title><source>Science</source><volume>347</volume><elocation-id>aaa2630</elocation-id><pub-id pub-id-type="doi">10.1126/science.aaa2630</pub-id><pub-id pub-id-type="pmid">25636800</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Qin</surname><given-names>N</given-names></name><name><surname>Qiao</surname><given-names>Y</given-names></name><name><surname>Xing</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Feng</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>STING, A promising target for small molecular immune modulator: A review</article-title><source>European Journal of Medicinal Chemistry</source><volume>211</volume><elocation-id>113113</elocation-id><pub-id pub-id-type="doi">10.1016/j.ejmech.2020.113113</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luksch</surname><given-names>H</given-names></name><name><surname>Stinson</surname><given-names>WA</given-names></name><name><surname>Platt</surname><given-names>DJ</given-names></name><name><surname>Qian</surname><given-names>W</given-names></name><name><surname>Kalugotla</surname><given-names>G</given-names></name><name><surname>Miner</surname><given-names>CA</given-names></name><name><surname>Bennion</surname><given-names>BG</given-names></name><name><surname>Gerbaulet</surname><given-names>A</given-names></name><name><surname>Rösen-Wolff</surname><given-names>A</given-names></name><name><surname>Miner</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>STING-associated lung disease in mice relies on T cells but not type I interferon</article-title><source>The Journal of Allergy and Clinical Immunology</source><volume>144</volume><fpage>254</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2019.01.044</pub-id><pub-id pub-id-type="pmid">30772497</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mansouri</surname><given-names>S</given-names></name><name><surname>Katikaneni</surname><given-names>DS</given-names></name><name><surname>Gogoi</surname><given-names>H</given-names></name><name><surname>Pipkin</surname><given-names>M</given-names></name><name><surname>Machuca</surname><given-names>TN</given-names></name><name><surname>Emtiazjoo</surname><given-names>AM</given-names></name><name><surname>Jin</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Lung IFNAR1hi TNFR2+ cDC2 promotes lung regulatory T cells induction and maintains lung mucosal tolerance at steady state</article-title><source>Mucosal Immunology</source><volume>13</volume><fpage>595</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1038/s41385-020-0254-1</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mansouri</surname><given-names>S</given-names></name><name><surname>Gogoi</surname><given-names>H</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Katikaneni</surname><given-names>DS</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Aybar-Torres</surname><given-names>A</given-names></name><name><surname>de Lartigue</surname><given-names>G</given-names></name><name><surname>Jin</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>MPYS modulates fatty acid metabolism and immune tolerance at homeostasis independent of type I IFNs</article-title><source>Journal of Immunology</source><volume>209</volume><fpage>2114</fpage><lpage>2132</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.2200158</pub-id><pub-id pub-id-type="pmid">36261171</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meric-Bernstam</surname><given-names>F</given-names></name><name><surname>Sweis</surname><given-names>RF</given-names></name><name><surname>Hodi</surname><given-names>FS</given-names></name><name><surname>Messersmith</surname><given-names>WA</given-names></name><name><surname>Andtbacka</surname><given-names>RHI</given-names></name><name><surname>Ingham</surname><given-names>M</given-names></name><name><surname>Lewis</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Pelletier</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>McWhirter</surname><given-names>SM</given-names></name><name><surname>Müller</surname><given-names>T</given-names></name><name><surname>Nair</surname><given-names>N</given-names></name><name><surname>Luke</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Phase I dose-escalation trial of MIW815 (ADU-S100), an Intratumoral STING agonist, in patients with advanced/metastatic solid tumors or lymphomas</article-title><source>Clinical Cancer Research</source><volume>28</volume><fpage>677</fpage><lpage>688</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-21-1963</pub-id><pub-id pub-id-type="pmid">34716197</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meric-Bernstam</surname><given-names>F</given-names></name><name><surname>Sweis</surname><given-names>RF</given-names></name><name><surname>Kasper</surname><given-names>S</given-names></name><name><surname>Hamid</surname><given-names>O</given-names></name><name><surname>Bhatia</surname><given-names>S</given-names></name><name><surname>Dummer</surname><given-names>R</given-names></name><name><surname>Stradella</surname><given-names>A</given-names></name><name><surname>Long</surname><given-names>GV</given-names></name><name><surname>Spreafico</surname><given-names>A</given-names></name><name><surname>Shimizu</surname><given-names>T</given-names></name><name><surname>Steeghs</surname><given-names>N</given-names></name><name><surname>Luke</surname><given-names>JJ</given-names></name><name><surname>McWhirter</surname><given-names>SM</given-names></name><name><surname>Müller</surname><given-names>T</given-names></name><name><surname>Nair</surname><given-names>N</given-names></name><name><surname>Lewis</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Bean</surname><given-names>A</given-names></name><name><surname>Kattenhorn</surname><given-names>L</given-names></name><name><surname>Pelletier</surname><given-names>M</given-names></name><name><surname>Sandhu</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in advanced/metastatic solid tumors or lymphomas: an open-label, multicenter, phase Ib study</article-title><source>Clinical Cancer Research</source><volume>29</volume><fpage>110</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-22-2235</pub-id><pub-id pub-id-type="pmid">36282874</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Messaoud-Nacer</surname><given-names>Y</given-names></name><name><surname>Culerier</surname><given-names>E</given-names></name><name><surname>Rose</surname><given-names>S</given-names></name><name><surname>Maillet</surname><given-names>I</given-names></name><name><surname>Rouxel</surname><given-names>N</given-names></name><name><surname>Briault</surname><given-names>S</given-names></name><name><surname>Ryffel</surname><given-names>B</given-names></name><name><surname>Quesniaux</surname><given-names>VFJ</given-names></name><name><surname>Togbe</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>STING agonist diABZI induces PANoptosis and DNA mediated acute respiratory distress syndrome (ARDS)</article-title><source>Cell Death &amp; Disease</source><volume>13</volume><elocation-id>269</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-022-04664-5</pub-id><pub-id pub-id-type="pmid">35338116</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monroe</surname><given-names>KM</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Johnson</surname><given-names>JR</given-names></name><name><surname>Geng</surname><given-names>X</given-names></name><name><surname>Doitsh</surname><given-names>G</given-names></name><name><surname>Krogan</surname><given-names>NJ</given-names></name><name><surname>Greene</surname><given-names>WC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>IFI16 DNA sensor is required for death of lymphoid CD4 T cells abortively infected with HIV</article-title><source>Science</source><volume>343</volume><fpage>428</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1126/science.1243640</pub-id><pub-id pub-id-type="pmid">24356113</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morou</surname><given-names>A</given-names></name><name><surname>Brunet-Ratnasingham</surname><given-names>E</given-names></name><name><surname>Dubé</surname><given-names>M</given-names></name><name><surname>Charlebois</surname><given-names>R</given-names></name><name><surname>Mercier</surname><given-names>E</given-names></name><name><surname>Darko</surname><given-names>S</given-names></name><name><surname>Brassard</surname><given-names>N</given-names></name><name><surname>Nganou-Makamdop</surname><given-names>K</given-names></name><name><surname>Arumugam</surname><given-names>S</given-names></name><name><surname>Gendron-Lepage</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Niessl</surname><given-names>J</given-names></name><name><surname>Baxter</surname><given-names>AE</given-names></name><name><surname>Billingsley</surname><given-names>JM</given-names></name><name><surname>Rajakumar</surname><given-names>PA</given-names></name><name><surname>Lefebvre</surname><given-names>F</given-names></name><name><surname>Johnson</surname><given-names>RP</given-names></name><name><surname>Tremblay</surname><given-names>C</given-names></name><name><surname>Routy</surname><given-names>J-P</given-names></name><name><surname>Wyatt</surname><given-names>RT</given-names></name><name><surname>Finzi</surname><given-names>A</given-names></name><name><surname>Douek</surname><given-names>DC</given-names></name><name><surname>Kaufmann</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Altered differentiation is central to HIV-specific CD4<sup>+</sup> T cell dysfunction in progressive disease</article-title><source>Nature Immunology</source><volume>20</volume><fpage>1059</fpage><lpage>1070</lpage><pub-id pub-id-type="doi">10.1038/s41590-019-0418-x</pub-id><pub-id pub-id-type="pmid">31308541</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motwani</surname><given-names>M</given-names></name><name><surname>Pawaria</surname><given-names>S</given-names></name><name><surname>Bernier</surname><given-names>J</given-names></name><name><surname>Moses</surname><given-names>S</given-names></name><name><surname>Henry</surname><given-names>K</given-names></name><name><surname>Fang</surname><given-names>T</given-names></name><name><surname>Burkly</surname><given-names>L</given-names></name><name><surname>Marshak-Rothstein</surname><given-names>A</given-names></name><name><surname>Fitzgerald</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Hierarchy of clinical manifestations in SAVI N153S and V154M mouse models</article-title><source>PNAS</source><volume>116</volume><fpage>7941</fpage><lpage>7950</lpage><pub-id pub-id-type="doi">10.1073/pnas.1818281116</pub-id><pub-id pub-id-type="pmid">30944222</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Movert</surname><given-names>E</given-names></name><name><surname>Bolarin</surname><given-names>JS</given-names></name><name><surname>Valfridsson</surname><given-names>C</given-names></name><name><surname>Velarde</surname><given-names>J</given-names></name><name><surname>Skrede</surname><given-names>S</given-names></name><name><surname>Nekludov</surname><given-names>M</given-names></name><name><surname>Hyldegaard</surname><given-names>O</given-names></name><name><surname>Arnell</surname><given-names>P</given-names></name><name><surname>Svensson</surname><given-names>M</given-names></name><name><surname>Norrby-Teglund</surname><given-names>A</given-names></name><name><surname>Cho</surname><given-names>KH</given-names></name><name><surname>Elhaik</surname><given-names>E</given-names></name><name><surname>Wessels</surname><given-names>MR</given-names></name><name><surname>Råberg</surname><given-names>L</given-names></name><name><surname>Carlsson</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Interplay between human STING genotype and bacterial NADase activity regulates inter-individual disease variability</article-title><source>Nature Communications</source><volume>14</volume><elocation-id>4008</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-023-39771-0</pub-id><pub-id pub-id-type="pmid">37414832</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murthy</surname><given-names>AMV</given-names></name><name><surname>Robinson</surname><given-names>N</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Crosstalk between cGAS-STING signaling and cell death</article-title><source>Cell Death and Differentiation</source><volume>27</volume><fpage>2989</fpage><lpage>3003</lpage><pub-id pub-id-type="doi">10.1038/s41418-020-00624-8</pub-id><pub-id pub-id-type="pmid">32948836</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nissen</surname><given-names>SK</given-names></name><name><surname>Pedersen</surname><given-names>JG</given-names></name><name><surname>Helleberg</surname><given-names>M</given-names></name><name><surname>Kjær</surname><given-names>K</given-names></name><name><surname>Thavachelvam</surname><given-names>K</given-names></name><name><surname>Obel</surname><given-names>N</given-names></name><name><surname>Tolstrup</surname><given-names>M</given-names></name><name><surname>Jakobsen</surname><given-names>MR</given-names></name><name><surname>Mogensen</surname><given-names>TH</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Multiple homozygous variants in the STING-encoding <italic>TMEM173</italic> Gene in HIV long-term nonprogressors</article-title><source>Journal of Immunology</source><volume>200</volume><fpage>3372</fpage><lpage>3382</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1701284</pub-id><pub-id pub-id-type="pmid">29632140</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Blaauboer</surname><given-names>SM</given-names></name><name><surname>Tucker</surname><given-names>HR</given-names></name><name><surname>Mansouri</surname><given-names>S</given-names></name><name><surname>Ruiz-Moreno</surname><given-names>JS</given-names></name><name><surname>Hamann</surname><given-names>L</given-names></name><name><surname>Schumann</surname><given-names>RR</given-names></name><name><surname>Opitz</surname><given-names>B</given-names></name><name><surname>Jin</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2017">2017a</year><article-title>The Common R71H-G230A-R293Q human TMEM173 is a null allele</article-title><source>Journal of Immunology</source><volume>198</volume><fpage>776</fpage><lpage>787</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1601585</pub-id><pub-id pub-id-type="pmid">27927967</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Blaauboer</surname><given-names>SM</given-names></name><name><surname>Tucker</surname><given-names>HR</given-names></name><name><surname>Mansouri</surname><given-names>S</given-names></name><name><surname>Ruiz-Moreno</surname><given-names>JS</given-names></name><name><surname>Hamann</surname><given-names>L</given-names></name><name><surname>Schumann</surname><given-names>RR</given-names></name><name><surname>Opitz</surname><given-names>B</given-names></name><name><surname>Jin</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2017">2017b</year><article-title>Response to comment on “the common R71H-G230A-R293Q Human <italic>TMEM173</italic> is a null allele.”</article-title><source>Journal of Immunology</source><volume>198</volume><fpage>4185</fpage><lpage>4188</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1700322</pub-id><pub-id pub-id-type="pmid">28533277</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Jin</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>TMEM173 variants and potential importance to human biology and disease</article-title><source>Genes and Immunity</source><volume>20</volume><fpage>82</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1038/s41435-018-0029-9</pub-id><pub-id pub-id-type="pmid">29728611</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pham</surname><given-names>AT</given-names></name><name><surname>Oliveira</surname><given-names>AC</given-names></name><name><surname>Albanna</surname><given-names>M</given-names></name><name><surname>Alvarez-Castanon</surname><given-names>J</given-names></name><name><surname>Dupee</surname><given-names>Z</given-names></name><name><surname>Patel</surname><given-names>D</given-names></name><name><surname>Fu</surname><given-names>C</given-names></name><name><surname>Mukhsinova</surname><given-names>L</given-names></name><name><surname>Nguyen</surname><given-names>A</given-names></name><name><surname>Jin</surname><given-names>L</given-names></name><name><surname>Bryant</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Non-interferon-dependent role of STING signaling in pulmonary hypertension</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>44</volume><fpage>124</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.123.320121</pub-id><pub-id pub-id-type="pmid">37942608</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Picard</surname><given-names>C</given-names></name><name><surname>Thouvenin</surname><given-names>G</given-names></name><name><surname>Kannengiesser</surname><given-names>C</given-names></name><name><surname>Dubus</surname><given-names>J-C</given-names></name><name><surname>Jeremiah</surname><given-names>N</given-names></name><name><surname>Rieux-Laucat</surname><given-names>F</given-names></name><name><surname>Crestani</surname><given-names>B</given-names></name><name><surname>Belot</surname><given-names>A</given-names></name><name><surname>Thivolet-Béjui</surname><given-names>F</given-names></name><name><surname>Secq</surname><given-names>V</given-names></name><name><surname>Ménard</surname><given-names>C</given-names></name><name><surname>Reynaud-Gaubert</surname><given-names>M</given-names></name><name><surname>Reix</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Severe pulmonary fibrosis as the first manifestation of interferonopathy (TMEM173 Mutation)</article-title><source>Chest</source><volume>150</volume><fpage>e65</fpage><lpage>e71</lpage><pub-id pub-id-type="doi">10.1016/j.chest.2016.02.682</pub-id><pub-id pub-id-type="pmid">27613991</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramanjulu</surname><given-names>JM</given-names></name><name><surname>Pesiridis</surname><given-names>GS</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Concha</surname><given-names>N</given-names></name><name><surname>Singhaus</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>S-Y</given-names></name><name><surname>Tran</surname><given-names>J-L</given-names></name><name><surname>Moore</surname><given-names>P</given-names></name><name><surname>Lehmann</surname><given-names>S</given-names></name><name><surname>Eberl</surname><given-names>HC</given-names></name><name><surname>Muelbaier</surname><given-names>M</given-names></name><name><surname>Schneck</surname><given-names>JL</given-names></name><name><surname>Clemens</surname><given-names>J</given-names></name><name><surname>Adam</surname><given-names>M</given-names></name><name><surname>Mehlmann</surname><given-names>J</given-names></name><name><surname>Romano</surname><given-names>J</given-names></name><name><surname>Morales</surname><given-names>A</given-names></name><name><surname>Kang</surname><given-names>J</given-names></name><name><surname>Leister</surname><given-names>L</given-names></name><name><surname>Graybill</surname><given-names>TL</given-names></name><name><surname>Charnley</surname><given-names>AK</given-names></name><name><surname>Ye</surname><given-names>G</given-names></name><name><surname>Nevins</surname><given-names>N</given-names></name><name><surname>Behnia</surname><given-names>K</given-names></name><name><surname>Wolf</surname><given-names>AI</given-names></name><name><surname>Kasparcova</surname><given-names>V</given-names></name><name><surname>Nurse</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Puhl</surname><given-names>AC</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Klein</surname><given-names>M</given-names></name><name><surname>Hopson</surname><given-names>CB</given-names></name><name><surname>Guss</surname><given-names>J</given-names></name><name><surname>Bantscheff</surname><given-names>M</given-names></name><name><surname>Bergamini</surname><given-names>G</given-names></name><name><surname>Reilly</surname><given-names>MA</given-names></name><name><surname>Lian</surname><given-names>Y</given-names></name><name><surname>Duffy</surname><given-names>KJ</given-names></name><name><surname>Adams</surname><given-names>J</given-names></name><name><surname>Foley</surname><given-names>KP</given-names></name><name><surname>Gough</surname><given-names>PJ</given-names></name><name><surname>Marquis</surname><given-names>RW</given-names></name><name><surname>Smothers</surname><given-names>J</given-names></name><name><surname>Hoos</surname><given-names>A</given-names></name><name><surname>Bertin</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Design of amidobenzimidazole STING receptor agonists with systemic activity</article-title><source>Nature</source><volume>564</volume><fpage>439</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0705-y</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruiz-Moreno</surname><given-names>JS</given-names></name><name><surname>Hamann</surname><given-names>L</given-names></name><name><surname>Shah</surname><given-names>JA</given-names></name><name><surname>Verbon</surname><given-names>A</given-names></name><name><surname>Mockenhaupt</surname><given-names>FP</given-names></name><name><surname>Puzianowska-Kuznicka</surname><given-names>M</given-names></name><name><surname>Naujoks</surname><given-names>J</given-names></name><name><surname>Sander</surname><given-names>LE</given-names></name><name><surname>Witzenrath</surname><given-names>M</given-names></name><name><surname>Cambier</surname><given-names>JC</given-names></name><name><surname>Suttorp</surname><given-names>N</given-names></name><name><surname>Schumann</surname><given-names>RR</given-names></name><name><surname>Jin</surname><given-names>L</given-names></name><name><surname>Hawn</surname><given-names>TR</given-names></name><name><surname>Opitz</surname><given-names>B</given-names></name><collab>CAPNETZ Study Group</collab></person-group><year iso-8601-date="2018">2018</year><article-title>The common HAQ STING variant impairs cGAS-dependent antibacterial responses and is associated with susceptibility to Legionnaires’ disease in humans</article-title><source>PLOS Pathogens</source><volume>14</volume><elocation-id>e1006829</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006829</pub-id><pub-id pub-id-type="pmid">29298342</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samson</surname><given-names>N</given-names></name><name><surname>Ablasser</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The cGAS-STING pathway and cancer</article-title><source>Nature Cancer</source><volume>3</volume><fpage>1452</fpage><lpage>1463</lpage><pub-id pub-id-type="doi">10.1038/s43018-022-00468-w</pub-id><pub-id pub-id-type="pmid">36510011</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sebastian</surname><given-names>M</given-names></name><name><surname>Hsiao</surname><given-names>CJ</given-names></name><name><surname>Futch</surname><given-names>HS</given-names></name><name><surname>Eisinger</surname><given-names>RS</given-names></name><name><surname>Dumeny</surname><given-names>L</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Gobena</surname><given-names>M</given-names></name><name><surname>Katikaneni</surname><given-names>DS</given-names></name><name><surname>Cohen</surname><given-names>J</given-names></name><name><surname>Carpenter</surname><given-names>AM</given-names></name><name><surname>Spiryda</surname><given-names>L</given-names></name><name><surname>Heldermon</surname><given-names>CD</given-names></name><name><surname>Jin</surname><given-names>L</given-names></name><name><surname>Brantly</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Obesity and STING1 genotype associate with 23-valent pneumococcal vaccination efficacy</article-title><source>JCI Insight</source><volume>5</volume><elocation-id>e136141</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.136141</pub-id><pub-id pub-id-type="pmid">32376795</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silvin</surname><given-names>A</given-names></name><name><surname>Manel</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Innate immune sensing of HIV infection</article-title><source>Current Opinion in Immunology</source><volume>32</volume><fpage>54</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2014.12.003</pub-id><pub-id pub-id-type="pmid">25617674</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skopelja-Gardner</surname><given-names>S</given-names></name><name><surname>An</surname><given-names>J</given-names></name><name><surname>Elkon</surname><given-names>KB</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Role of the cGAS-STING pathway in systemic and organ-specific diseases</article-title><source>Nature Reviews. Nephrology</source><volume>18</volume><fpage>558</fpage><lpage>572</lpage><pub-id pub-id-type="doi">10.1038/s41581-022-00589-6</pub-id><pub-id pub-id-type="pmid">35732833</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Horecny</surname><given-names>I</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Miller</surname><given-names>M</given-names></name><name><surname>Chowdhury</surname><given-names>R</given-names></name><name><surname>Issa</surname><given-names>M</given-names></name><name><surname>Shen</surname><given-names>R</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Bai</surname><given-names>C</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name><name><surname>Zhuang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Wilkinson</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Tao</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>SHR1032, a novel STING agonist, stimulates anti-tumor immunity and directly induces AML apoptosis</article-title><source>Scientific Reports</source><volume>12</volume><elocation-id>8579</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-022-12449-1</pub-id><pub-id pub-id-type="pmid">35595822</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stinson</surname><given-names>WA</given-names></name><name><surname>Miner</surname><given-names>CA</given-names></name><name><surname>Zhao</surname><given-names>FR</given-names></name><name><surname>Lundgren</surname><given-names>AJ</given-names></name><name><surname>Poddar</surname><given-names>S</given-names></name><name><surname>Miner</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The IFN-γ receptor promotes immune dysregulation and disease in STING gain-of-function mice</article-title><source>JCI Insight</source><volume>7</volume><elocation-id>e155250</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.155250</pub-id><pub-id pub-id-type="pmid">36073546</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szego</surname><given-names>EM</given-names></name><name><surname>Malz</surname><given-names>L</given-names></name><name><surname>Bernhardt</surname><given-names>N</given-names></name><name><surname>Rösen-Wolff</surname><given-names>A</given-names></name><name><surname>Falkenburger</surname><given-names>BH</given-names></name><name><surname>Luksch</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Constitutively active STING causes neuroinflammation and degeneration of dopaminergic neurons in mice</article-title><source>eLife</source><volume>11</volume><elocation-id>e81943</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.81943</pub-id><pub-id pub-id-type="pmid">36314770</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>C-HA</given-names></name><name><surname>Zundell</surname><given-names>JA</given-names></name><name><surname>Ranatunga</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>C</given-names></name><name><surname>Nefedova</surname><given-names>Y</given-names></name><name><surname>Del Valle</surname><given-names>JR</given-names></name><name><surname>Hu</surname><given-names>C-CA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Agonist-mediated activation of sting induces apoptosis in malignant B Cells</article-title><source>Cancer Research</source><volume>76</volume><fpage>2137</fpage><lpage>2152</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-1885</pub-id><pub-id pub-id-type="pmid">26951929</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>STING-associated vasculopathy with onset in infancy in three children with new clinical aspect and unsatisfactory therapeutic responses to Tofacitinib</article-title><source>Journal of Clinical Immunology</source><volume>40</volume><fpage>114</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1007/s10875-019-00690-9</pub-id><pub-id pub-id-type="pmid">31705453</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vila</surname><given-names>IK</given-names></name><name><surname>Chamma</surname><given-names>H</given-names></name><name><surname>Steer</surname><given-names>A</given-names></name><name><surname>Saccas</surname><given-names>M</given-names></name><name><surname>Taffoni</surname><given-names>C</given-names></name><name><surname>Turtoi</surname><given-names>E</given-names></name><name><surname>Reinert</surname><given-names>LS</given-names></name><name><surname>Hussain</surname><given-names>S</given-names></name><name><surname>Marines</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>L</given-names></name><name><surname>Bonnefont</surname><given-names>X</given-names></name><name><surname>Hubert</surname><given-names>M</given-names></name><name><surname>Schwartz</surname><given-names>O</given-names></name><name><surname>Paludan</surname><given-names>SR</given-names></name><name><surname>Van Simaeys</surname><given-names>G</given-names></name><name><surname>Doumont</surname><given-names>G</given-names></name><name><surname>Sobhian</surname><given-names>B</given-names></name><name><surname>Vlachakis</surname><given-names>D</given-names></name><name><surname>Turtoi</surname><given-names>A</given-names></name><name><surname>Laguette</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>STING orchestrates the crosstalk between polyunsaturated fatty acid metabolism and inflammatory responses</article-title><source>Cell Metabolism</source><volume>34</volume><fpage>125</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2021.12.007</pub-id><pub-id pub-id-type="pmid">34986331</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volpi</surname><given-names>S</given-names></name><name><surname>Insalaco</surname><given-names>A</given-names></name><name><surname>Caorsi</surname><given-names>R</given-names></name><name><surname>Santori</surname><given-names>E</given-names></name><name><surname>Messia</surname><given-names>V</given-names></name><name><surname>Sacco</surname><given-names>O</given-names></name><name><surname>Terheggen-Lagro</surname><given-names>S</given-names></name><name><surname>Cardinale</surname><given-names>F</given-names></name><name><surname>Scarselli</surname><given-names>A</given-names></name><name><surname>Pastorino</surname><given-names>C</given-names></name><name><surname>Moneta</surname><given-names>G</given-names></name><name><surname>Cangemi</surname><given-names>G</given-names></name><name><surname>Passarelli</surname><given-names>C</given-names></name><name><surname>Ricci</surname><given-names>M</given-names></name><name><surname>Girosi</surname><given-names>D</given-names></name><name><surname>Derchi</surname><given-names>M</given-names></name><name><surname>Bocca</surname><given-names>P</given-names></name><name><surname>Diociaiuti</surname><given-names>A</given-names></name><name><surname>El Hachem</surname><given-names>M</given-names></name><name><surname>Cancrini</surname><given-names>C</given-names></name><name><surname>Tomà</surname><given-names>P</given-names></name><name><surname>Granata</surname><given-names>C</given-names></name><name><surname>Ravelli</surname><given-names>A</given-names></name><name><surname>Candotti</surname><given-names>F</given-names></name><name><surname>Picco</surname><given-names>P</given-names></name><name><surname>DeBenedetti</surname><given-names>F</given-names></name><name><surname>Gattorno</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>efficacy and adverse events during janus kinase inhibitor treatment of SAVI syndrome</article-title><source>Journal of Clinical Immunology</source><volume>39</volume><fpage>476</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1007/s10875-019-00645-0</pub-id><pub-id pub-id-type="pmid">31144250</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warner</surname><given-names>JD</given-names></name><name><surname>Irizarry-Caro</surname><given-names>RA</given-names></name><name><surname>Bennion</surname><given-names>BG</given-names></name><name><surname>Ai</surname><given-names>TL</given-names></name><name><surname>Smith</surname><given-names>AM</given-names></name><name><surname>Miner</surname><given-names>CA</given-names></name><name><surname>Sakai</surname><given-names>T</given-names></name><name><surname>Gonugunta</surname><given-names>VK</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Platt</surname><given-names>DJ</given-names></name><name><surname>Yan</surname><given-names>N</given-names></name><name><surname>Miner</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>STING-associated vasculopathy develops independently of IRF3 in mice</article-title><source>The Journal of Experimental Medicine</source><volume>214</volume><fpage>3279</fpage><lpage>3292</lpage><pub-id pub-id-type="doi">10.1084/jem.20171351</pub-id><pub-id pub-id-type="pmid">28951494</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>YJ</given-names></name><name><surname>Dobbs</surname><given-names>N</given-names></name><name><surname>Sakai</surname><given-names>T</given-names></name><name><surname>Liou</surname><given-names>J</given-names></name><name><surname>Miner</surname><given-names>JJ</given-names></name><name><surname>Yan</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>STING-mediated disruption of calcium homeostasis chronically activates ER stress and primes T cell death</article-title><source>The Journal of Experimental Medicine</source><volume>216</volume><fpage>867</fpage><lpage>883</lpage><pub-id pub-id-type="doi">10.1084/jem.20182192</pub-id><pub-id pub-id-type="pmid">30886058</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Dobbs</surname><given-names>N</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Yan</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Interferon-independent activities of mammalian STING mediate antiviral response and tumor immune evasion</article-title><source>Immunity</source><volume>53</volume><fpage>115</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.06.009</pub-id><pub-id pub-id-type="pmid">32640258</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamashiro</surname><given-names>LH</given-names></name><name><surname>Wilson</surname><given-names>SC</given-names></name><name><surname>Morrison</surname><given-names>HM</given-names></name><name><surname>Karalis</surname><given-names>V</given-names></name><name><surname>Chung</surname><given-names>J-YJ</given-names></name><name><surname>Chen</surname><given-names>KJ</given-names></name><name><surname>Bateup</surname><given-names>HS</given-names></name><name><surname>Szpara</surname><given-names>ML</given-names></name><name><surname>Lee</surname><given-names>AY</given-names></name><name><surname>Cox</surname><given-names>JS</given-names></name><name><surname>Vance</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Interferon-independent STING signaling promotes resistance to HSV-1 in vivo</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>3382</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-17156-x</pub-id><pub-id pub-id-type="pmid">32636381</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>Q</given-names></name><name><surname>Zeng</surname><given-names>W</given-names></name><name><surname>Shao</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Diao</surname><given-names>H</given-names></name><name><surname>Rong</surname><given-names>X</given-names></name><name><surname>Bai</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Mitochondrial damage and activation of the cytosolic DNA sensor cGAS-STING pathway lead to cardiac pyroptosis and hypertrophy in diabetic cardiomyopathy mice</article-title><source>Cell Death Discovery</source><volume>8</volume><elocation-id>258</elocation-id><pub-id pub-id-type="doi">10.1038/s41420-022-01046-w</pub-id><pub-id pub-id-type="pmid">35538059</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>G</given-names></name><name><surname>Brendel</surname><given-names>VP</given-names></name><name><surname>Shu</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Palanathan</surname><given-names>S</given-names></name><name><surname>Cheng Kao</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Single nucleotide polymorphisms of human STING can affect innate immune response to cyclic dinucleotides</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e77846</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0077846</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Mo</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>T</given-names></name><name><surname>Zhuo</surname><given-names>W</given-names></name><name><surname>Yi</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Yin</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy</article-title><source>Molecular Cancer</source><volume>19</volume><elocation-id>133</elocation-id><pub-id pub-id-type="doi">10.1186/s12943-020-01250-1</pub-id><pub-id pub-id-type="pmid">32854711</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.96790.3.sa0</article-id><title-group><article-title>eLife assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rothlin</surname><given-names>Carla V</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Yale University</institution><country>United States</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Incomplete</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Useful</kwd></kwd-group></front-stub><body><p>This study describes <bold>useful</bold> mouse models of knock-ins of human STING1 variants and an assessment of these variants' action in mouse immune cells. While the implications of the variants in the inflammatory response are of significant interest, limitations are still found in the authors' interpretation and conclusions made, and the evidence for the conclusion remains <bold>incomplete</bold>.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.96790.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>This manuscript by Aybar-Torres et al investigated the effect of common human STING1 variants on STING-mediated T cell phenotypes in mice. The authors previously made knock-in mice expressing human STING1 alleles HAQ or AQ, and here they established a new knock-in line Q293. The authors stimulated cells isolated from these mice with STING agonists and found that all three human mutant alleles resist cell death, leading to the conclusion that R293 residue is essential for STING-mediated cell death (there are several caveats with this conclusion, more below). The authors also bred HAQ and AQ alleles to the mouse Sting1-N153S SAVI mouse and observed varying levels of rescue of disease phenotypes with the AQ allele showing more complete rescue than the HAQ allele. The Q293 allele was not tested in the SAVI model. They conclude that the human common variants such as HAQ and AQ have a dominant negative effect over the gain-of-function SAVI mutants.</p><p>Strengths:</p><p>The authors and Dr. Jin's group previously made important observations of common human STING1 variants, and these knock-in mouse models are essential for understanding the physiological function of these alleles.</p><p>Weaknesses:</p><p>However, although some of the observations reported here are interesting, the data collectively does not support a unified model. The authors seem to be drawing two sets of conclusions from in vitro and in vivo experiments, and neither mechanism is clear. Several experiments need better controls, and these knock-in mice need more comprehensive functional characterization.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.96790.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Aybar-Torres and colleagues utilize common human STING alleles to dissect the mechanism of SAVI inflammatory disease. The authors demonstrate that these common alleles alleviate SAVI pathology in mice, and perhaps more importantly use the differing functionality of these alleles to provide insight into requirements of SAVI disease induction. Their findings suggest that it is residue A230 and/or Q293 that are required for SAVI induction, while the ability to induce an interferon-dependent inflammatory response is not. This is nicely exemplified by the AQ/SAVI mice that have an intact inflammatory response to STING activation, yet minimal disease progression. As both mutants seem to be resistant STING-dependent cell death, this manuscript also alludes to the importance of STING-dependent cell death, rather than STING-dependent inflammation, in the progression of SAVI pathology. I believe this manuscript makes some important connections between STING pathology mouse models and human genetics that would contribute to the field.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.96790.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Aybar-Torres</surname><given-names>Alexandra a</given-names></name><role specific-use="author">Author</role><aff><institution>University of Florida</institution><addr-line><named-content content-type="city">Gainesville</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Saldarriaga</surname><given-names>Lennon A</given-names></name><role specific-use="author">Author</role><aff><institution>The University of Florida</institution><addr-line><named-content content-type="city">Gainesville</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Pham</surname><given-names>Ann t</given-names></name><role specific-use="author">Author</role><aff><institution>The University of Florida</institution><addr-line><named-content content-type="city">Gainesville</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Emtiazjoo</surname><given-names>Amir m</given-names></name><role specific-use="author">Author</role><aff><institution>The University of Florida</institution><addr-line><named-content content-type="city">Gainesville</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Ashish k</given-names></name><role specific-use="author">Author</role><aff><institution>The University of Florida</institution><addr-line><named-content content-type="city">Gainesville</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Bryant</surname><given-names>Andrew j</given-names></name><role specific-use="author">Author</role><aff><institution>The University of Florida</institution><addr-line><named-content content-type="city">Gainesville</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Jin</surname><given-names>Lei</given-names></name><role specific-use="author">Author</role><aff><institution>University of Florida</institution><addr-line><named-content content-type="city">Gainesville</named-content></addr-line><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><p>Summary Responses: Besides the <italic>WT</italic> allele, equivalent to the mouse <italic>TMEM173</italic> gene, the human <italic>TMEM173</italic> gene has two common alleles: the <italic>HAQ</italic> and <italic>AQ</italic> alleles carried by billions of people. The main conclusions and interpretation, summarized in the Title and Abstract, are (i) Different from the <italic>WT TMEM173</italic> allele, the <italic>HAQ</italic> or <italic>AQ</italic> alleles are resistant to STING activation-induced cell death; (ii) STING residue 293 is critical for cell death; (iii) <italic>HAQ, AQ</italic> alleles are dominant to the <italic>SAVI</italic> allele; (iv) One copy of the <italic>AQ</italic> allele rescues the SAVI disease in mice. We propose that STING research and STING-targeting immunotherapy should consider human <italic>TMEM173</italic> heterogeneity. These interpretations and conclusions were based on Data and Logic. We welcome alternative, logical interpretations and collaborations to advance the human <italic>TMEM173</italic> research.</p><disp-quote content-type="editor-comment"><p><bold>Public Reviews:</bold></p><p><bold>Reviewer #1 (Public Review):</bold></p><p>Summary:</p><p>This manuscript by Aybar-Torres et al investigated the effect of common human STING1 variants on STING-mediated T cell phenotypes in mice. The authors previously made knock-in mice expressing human STING1 alleles HAQ or AQ, and here they established a new knock-in line Q293. The authors stimulated cells isolated from these mice with STING agonists and found that all three human mutant alleles resist cell death, leading to the conclusion that R293 residue is essential for STING-mediated cell death (there are several caveats with this conclusion, more below). The authors also bred HAQ and AQ alleles to the mouse Sting1-N153S SAVI mouse and observed varying levels of rescue of disease phenotypes with the AQ allele showing more complete rescue than the HAQ allele. The Q293 allele was not tested in the SAVI model. They conclude that the human common variants such as HAQ and AQ have a dominant negative effect over the gain-of-function SAVI mutants.</p><p>Strengths:</p><p>The authors and Dr. Jin's group previously made important observations of common human STING1 variants, and these knock-in mouse models are essential for understanding the physiological function of these alleles.</p><p>Weaknesses:</p><p>However, although some of the observations reported here are interesting, the data collectively does not support a unified model. The authors seem to be drawing two sets of conclusions from in vitro and in vivo experiments, and neither mechanism is clear. Several experiments need better controls, and these knock-in mice need more comprehensive functional characterization.</p><p>(1) In Figure 1, the authors are trying to show that STING agonist-induced splenocytes cell death is blocked by HAQ, AQ and Q alleles. The conclusion at line 134 should be splenocytes, not lymphocytes. Most experiments in this figure were done with mixed population that may involve cell-to-cell communication. Although TBK1-dependence is likely, a single inhibitor treatment of a mixed population is not sufficient to reach this conclusion.</p></disp-quote><p>We greatly appreciate Reviewer 1's insights. We changed the “lymphocytes” to “splenocytes” (line 133) as suggested. We respectfully disagree with Reviewer 1’s comments on TBK1. First, we used two different TBK1 inhibitors: BX795 and GSK8612. Second, because BX795 also inhibits PDK1, we used a PDK1 inhibitor GSK2334470; Third, both BX795 and GSK8612 completely inhibited diABZI-induced splenocyte cell death (Figure 1B) (lines 128 – 133). The logical conclusion is “<italic>TBK1 activation is required for STING-mediated mouse spleen cell death</italic> ex vivo<italic>”</italic>. (line 117).</p><p>Our discovery that the common human <italic>TMEM173</italic> alleles are resistant to STING activation-induced cell death is a substantial finding. It further strengthens the argument that the <italic>HAQ</italic> and <italic>AQ</italic> alleles are functionally distinct from the <italic>WT</italic> allele 1-3. We wish to underscore the crucial message of this study-that <italic>'STING research and STING-targeting immunotherapy should consider TMEM173 heterogeneity in humans</italic>' (line 37), which has been largely overlooked in current STING clinical trials 4.</p><p>Regarding STING-Cell death, as we stated in the Introduction (lines 65-77). (i) STING-mediated cell death is cell type-dependent 5-7 and type I IFNs-independent 5,7,8. (ii) The in vivo biological significance of STING-mediated cell death is not clear 7,8. (iii) The mechanisms of STING-Cell death remain controversial. Multiple cell death pathways, i.e., apoptosis, necroptosis, pyroptosis, ferroptosis, and PANoptosis, are proposed 7,9,10. <italic>SAVI/HAQ</italic>, <italic>SAVI/AQ</italic> prevented lymphopenia and alleviated SAVI disease in mice. Thus, the manuscript provides some answers to the biological significance of STING-cell death in vivo, which is new. Regarding the molecular mechanism, splenocytes from <italic>Q293/Q293</italic> mice are resistant to STING cell death. The logical conclusion is that the amino acid 293 is critical for STING cell death (line 29).</p><p>Extensive studies are needed, beyond the scope of this manuscript, on how aa293 and TBK1 mediates STING-Cell death to resolve the controversies in the STING-cell death fields (<italic>e.g.</italic> apoptosis, necroptosis, pyroptosis, ferroptosis, and PANoptosis).</p><disp-quote content-type="editor-comment"><p>(2) Q293 knock-in mouse needs to be characterized and compared to HAQ and AQ. Is this mutant expressed in tissues? Does this mutant still produce IFN and other STING activities? Does the protein expression level altered on Western blot? Is the mutant protein trafficking affected? In the authors' previous publications and some of the Western blot here, expression levels of each of these human STING1 protein in mice are drastically different. HAQ and AQ also have different effects on metabolism (pmid: 36261171), which could complicate interoperation of the T cell phenotypes.</p></disp-quote><p>These are very important questions that require rigorous investigations that are beyond the scope of this manuscript. This manuscript, titled “<italic>The common TMEM173 HAQ, AQ alleles rescue CD4 T cellpenia, restore T-regs, and prevent SAVI (N153S) inflammatory disease in mice</italic>” does not focus on Q293 mice. We have been investigating the common human <italic>TMEM173</italic> alleles since 2011 from the discovery 11 , mouse model 1,3, human clinical trial 2, and human genetics studies 3. This manuscript is another step towards understanding these common human <italic>TMEM173</italic> alleles with the new discovery that <italic>HAQ, AQ</italic> alleles are resistant to STING cell death.</p><disp-quote content-type="editor-comment"><p>(3) HAQ/WT and AQ/WT splenocytes are protected from STING agonist-induced cell death equally well (Figure 1G). HAQ/SAVI shows less rescue compared to AQ/SAVI. These are interesting observations, but mechanism is unclear and not clearly discussed. E.g., how does AQ protect disease pathology better than HAQ (that contains AQ)? Does Q293 allele also fully rescue SAVI?</p></disp-quote><p>In this manuscript, Figure 6 shows <italic>AQ/SAVI</italic> had more T-regs than <italic>HAQ/SAVI</italic> (lines 251 – 261). In our previous publication on <italic>HAQ, AQ</italic> knockin mice, we showed that <italic>AQ</italic> T-regs have more IL-10 than <italic>HAQ</italic> T-regs 3. Thus, increased IL-10+ Tregs in <italic>AQ</italic> mice may contribute to an improved phenotype in <italic>AQ/SAVI</italic> compared to <italic>HAQ/SAVI.</italic> However, we are not excluding other contributions (e.g. metabolic difference) (lines 332-335). We are exploring these possibilities.</p><disp-quote content-type="editor-comment"><p>(4) Figure 2 feels out of place. First of all, why are the authors using human explant lung tissues? PBMCs should be a better source for lymphocytes. In untreated conditions, both CD4 and B cells show ~30% dying cells, but CD8 cells show 0% dying cells. This calls for technical concerns on the CD8 T cell property or gating strategy because in the mouse experiment (Figure 1A) all primary lymphocytes show ~30% cell death at steady-state. Second, Figure 2C, these type of partial effect needs multiple human donors to confirm. Three, the reconstitution of THP1 cells seems out of place. STING-mediated cell death mechanism in myeloid and lymphoid cells are likely different. If the authors want to demonstrate cell death in myeloid cells using THP1, then these reconstituted cell lines need to be better validated. Expression, IFN signaling, etc. The parental THP1 cells is HAQ/HAQ, how does that compare to the reconstitutions? There are published studies showing THP1-STING-KO cells reconstituted with human variants do not respond to STING agonists as expected. The authors need to be scientifically rigorous on validation and caution on their interpretations.</p></disp-quote><p>Figure 2 is necessary because it reveals the difference between mouse and human STING cell death, which is critical to understand STING in human health and diseases (lines 160-161). Figure 2A-2B showed that STING activation killed human CD4 T cells, but not human CD8 T cells or B cells. This observation is different from Figure 1A, where STING activation killed mouse CD4, CD8 T cells, and CD19 B cells, revealing the species-specific STING cell death responses. Regarding human CD8 T cells, as we stated in the Discussion (lines 323-325), human CD8 T cells (PBMC) are not as susceptible as the CD4 T cells to STING-induced cell death 8. We used lung lymphocytes that showed similar observations (Figure 2A). For Figure 2C, we used 2 WT/HAQ and 3 WT/WT individuals (lines 738-739). We generate HAQ, AQ THP-1 cells in STING-KO THP-1 cells (Invivogen,, cat no. thpd-kostg) (lines 380-387).</p><p>A recent study found that a new STING agonist SHR1032 induces cell death in STING-KO THP-1 cells expressing WT(R232) human STING 10 (line 182). SHR1032 suppressed THP1-STING-WT(R232) cell growth at GI50: 23 nM while in the parental THP1-STING-HAQ cells, the GI50 of SHR1032 was &gt;103 nM 10. Cytarabine was used as an internal control where SHR1032 killed more robustly than cytarabine in the THP1-STING-WT(R232) cells but much less efficiently than cytarabine in the THP-1-STING-HAQ cells 10.</p><p>Our manuscript rigorously uses mouse splenocytes, human lung lymphocytes, THP-1 reconstituted with HAQ, AQ, and HAQ/SAVI, AQ/SAVI mice, to demonstrate that the common human HAQ, AQ alleles are resistant to STING cell death in vitro and in vivo.</p><p>We agree with Reviewer 1 that STING-mediated cell death mechanisms in myeloid and lymphoid cells may be different and likely contribute to the different mechanisms proposed in STING cell death research 7,9,10. Our study focuses on the in vivo STING-mediated T cellpenia.</p><disp-quote content-type="editor-comment"><p>(5) Figure 2G, H, I are confusing. AQ is more active in producing IFN signaling than HAQ and Q is the least active. How to explain this?</p></disp-quote><p>We stated in the Introduction that “<italic>AQ</italic> responds to CDNs and produce type I IFNs in vivo and in vitro 3,12,13 ”(line 92-93). We reported that the <italic>AQ</italic> knock in mice responded to STING activation 3. We previously showed that there was a negative natural selection on the <italic>AQ</italic> allele in individuals outside of Africa 3. 28% of Africans are <italic>WT/AQ</italic> but only 0.6% East Asians are <italic>WT/AQ</italic> 3. In contrast, the <italic>HAQ</italic> allele was positively selected in non-Africans 3. Investigation to understand the mechanisms and biological significance of these naturally selected human <italic>TMEM173</italic> alleles has been ongoing in the lab.</p><disp-quote content-type="editor-comment"><p>(6) The overall model is unclear. If HAQ, AQ and Q are loss-of-function alleles and Q is the key residue for STING-mediated cell death, then why AQ is the most active in producing IFN signaling and AQ/SAVI rescues disease most completely? If these human variants act as dominant negatives, which would be consistent with the WT/het data, then how do you explain AQ is more dominant negative than HAQ?</p></disp-quote><p>In this manuscript, Figure 6 shows <italic>AQ/SAVI</italic> had more T-regs than <italic>HAQ/SAVI</italic> (lines 251 – 261). In our previous publication on <italic>HAQ, AQ</italic> knockin mice, we showed that <italic>AQ</italic> T-regs have more IL-10 and mitochondria activity than <italic>HAQ</italic> T-regs 3. Nevertheless, we are not excluding other contributions (e.g. metabolic difference) by the <italic>AQ</italic> allele (lines 332-335). Last, we used modern human evolution to discover the dominance of these common human STING alleles. In modern humans outside Africans, <italic>HAQ</italic> was positively selected while <italic>AQ</italic> was negatively selected 3. However, <italic>AQ</italic> is likely dominant to <italic>HAQ</italic> because there is no <italic>HAQ/AQ</italic> individuals outside Africa. The genetic dominance of common human <italic>TMEM173</italic> allele is a new concept. More investigation is ongoing.</p><disp-quote content-type="editor-comment"><p>(7) As a general note, SAVI disease phenotypes involve multiple cell types. Lymphocyte cell death is only one of them. The authors' characterization of SAVI pathology is limited and did not analyze immunopathology of the lung.</p></disp-quote><p>Both radioresistant parenchymal and/or stromal cells and hematopoietic cells influence SAVI pathology in mice 14,15. Nevertheless, the lack of CD 4 T cells, including the anti-inflammatory T-regs, likely contributes to the inflammation in SAVI mice and patients 16. We characterized lung function, lung inflammation (Figure 4), lung neutrophils, and inflammatory monocyte infiltration (Figure S5) (lines 232-235).</p><disp-quote content-type="editor-comment"><p>(8) Line 281, the discussion on HIV T cell death mechanism is not relevant and over-stretching. This study did not evaluate viral infection in T cells at all. The original finding of HAQ/HAQ enrichment in HIV/AIDS was 2/11 in LTNP vs 0/11 in control, arguably not the strongest statistics.</p></disp-quote><p>Several publications have linked STING to HIV pathogenesis 17-22 (line 271). CD4 T cellpenia is a hallmark of AIDS. The manuscript studies STING activation-induced T cellpenia in vivo. It is not stretching to ask, for example, does preventing STING T cell death (e.g <italic>HAQ, AQ</italic> alleles) can restore CD4 T cell counts and improve care for AIDS patients?</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public Review):</bold></p><p>Aybar-Torres and colleagues utilize common human STING alleles to dissect the mechanism of SAVI inflammatory disease. The authors demonstrate that these common alleles alleviate SAVI pathology in mice, and perhaps more importantly use the differing functionality of these alleles to provide insight into requirements of SAVI disease induction. Their findings suggest that it is residue A230 and/or Q293 that are required for SAVI induction, while the ability to induce an interferon-dependent inflammatory response is not. This is nicely exemplified by the AQ/SAVI mice that have an intact inflammatory response to STING activation, yet minimal disease progression. As both mutants seem to be resistant STING-dependent cell death, this manuscript also alludes to the importance of STING-dependent cell death, rather than STING-dependent inflammation, in the progression of SAVI pathology. While I have some concerns, I believe this manuscript makes some important connections between STING pathology mouse models and human genetics that would contribute to the field.</p><p>Some points to consider:</p><p>(1) While the CD4+ T cell counts from HAQ/SAVI and AQ/SAVI mice suggest that these T cells are protected from STING-dependent cell death, an assay that explores this more directly would strengthen the manuscript. This is also supported by Fig 2C, but I believe a strength of this manuscript is the comparison between the two alleles. Therefore, if possible, I would recommend the isolation of T cells from these mice and direct stimulation with diABZI or other STING agonist with a cell death readout.</p></disp-quote><p>Please see the new Figure S3 for cell death by diABZI, DMXAA in Splenocytes from <italic>WT/WT, WT/HAQ, HAQ/SAVI, AQ/SAVI</italic> mice. The <italic>HAQ/SAVI</italic> and <italic>AQ/SAVI</italic> splenocytes showed similar partial resistance to STING activation-induced cell death (lines 214-216).</p><disp-quote content-type="editor-comment"><p>(2) Related to the above point - further exemplifying that the Q293 locus is essential to disease, even in human cells, would also strengthen the paper. It seems that CD4 T cell loss is a major component of human SAVI. While not co_mpletely necessary, repeating the THP1 cell death experiments from Fig 2 with a human T cell line would round out the study nicely._</p></disp-quote><p>We examined <italic>HAQ, AQ</italic> mouse splenocytes, <italic>HAQ</italic> human lung lymphocytes, THP-1 reconstituted with <italic>HAQ, AQ,</italic> and <italic>HAQ/SAVI, AQ/SAVI</italic> mice, to demonstrate that the common human <italic>HAQ, AQ</italic> alleles are resistant to STING cell death in vitro and in vivo. Additional human T cell line work does not add too much. We hope to conduct more human PBMC or lung lymphocytes STING cell death experiments from <italic>HAQ, AQ</italic> individuals as we continue the human <italic>STING</italic> alleles investigation.</p><disp-quote content-type="editor-comment"><p>(3) While I found the myeloid cell counts and BMDM data interesting, I think some more context is needed to fully loop this data into the story. Is myeloid cell expansion exemplified by SAVI patients? Do we know if myeloid cells are the major contributors to the inflammation these patients experience? Why should the SAVI community care about the Q293 locus in myeloid cells?</p></disp-quote><p>This is likely a misunderstanding. We use BMDM for the purpose of comparing STING signaling (TBK1, IRF3, NFkB, STING activation) by <italic>WT/SAVI, HAQ/SAVI, AQ/SAVI</italic>. Ideally, we would like to compare STING signaling in CD4 T cells from <italic>WT/SAVI to HAQ/SAVI, AQ/SAVI</italic> mice. However, <italic>WT/SAVI</italic> has no CD4 T cells. Doing so, we are making the assumption that the basic STING signaling (TBK1, IRF3, NFkB, STING activation) is conserved between T cells and macrophages.</p><disp-quote content-type="editor-comment"><p>(4) The functional assays in Figure 4 are exciting and really connect the alleles to disease progression. To strengthen the manuscript and connect all the data, I would recommend additional readouts from these mice that address the inflammatory phenotype shown in vitro in Figure 5. For example, measuring cytokines from these mice via ELISA or perhaps even Western blots looking for NFkB or STING activation would be supportive of the story. This would also allow for some tissue specificity. I believe looking for evidence of inflammation and STING activation in the lungs of these mice, for example, would further connect the data to human SAVI pathology.</p></disp-quote><p>Reviewer 2 suggests looking for evidence of inflammation and STING activation in the lungs of <italic>HAQ/SAVI, AQ/SAVI</italic>. We would like to elaborate further. First, anti-inflammatory treatments, e.g. steroids, DMARDs, IVIG, Etanercept (TNF), rituximab, Nifedipine, amlodipine, et al., all failed in SAVI patients 23. JAK inhibitors on SAVI had mixed outcomes (lines 55-58). Second, Figure S5 examined lung neutrophils and inflammatory monocyte infiltration. Interestingly, while <italic>AQ/SAVI</italic> mice had a better lung function than <italic>HAQ/SAVI</italic> mice (Figure 4D, 4E vs 4H, 4I), <italic>HAQ/SAVI</italic> and <italic>AQ/SAVI</italic> lungs had comparable neutrophils and inflammatory monocyte infiltration (Figure S5). Last, SAVI is classified as type I interferonopathy 23, but the lung diseases of SAVI are mainly independent of type I IFNs 24-27. The <italic>AQ</italic> allele suppresses SAVI in vivo. Understanding the mechanisms by which <italic>AQ</italic> rescues SAVI may lead to curative care for SAVI patients.</p><disp-quote content-type="editor-comment"><p><bold>Recommendations for the authors:</bold></p><p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p><p>One suggestion is to streamline this study by focusing on STING-mediated cell death only in CD4 T cells. The authors can use in vitro PBMC isolated human T cells, ex vivo T cells from the knock-in mice, and in vivo T cells from the SAVI breeding. The current manuscript includes myeloid cell death, Tregs, complex SAVI disease pathology, which is too confusing and too complex to explain with the varying effect from the three human STING1 variants.</p></disp-quote><p>We sincerely appreciate Reviewer 1’s suggestion. The goal of our human <italic>STING</italic> alleles research has always been translational, i.e. improving human health. Even as a monogenetic disease, the SAVI pathology is still complex. For example, thought as a type I Interferonopathy, SAVI is largely independent of type I IFNs. Similarly, STING-activation-induced cell death, while contribute to SAVI, is not the whole story, as the Reviewer pointed out in the Comment 3 &amp; 6 &amp;7. <italic>HAQ/SAVI</italic> mice still died early and had lung dysfunction (Figure 4). In contrast, <italic>AQ/SAVI</italic> mice restore lifespan and lung function. We had Figure 6 show different T-regs between <italic>AQ/SAVI</italic> and <italic>HAQ/SAVI</italic> mice. In addition, <italic>AQ</italic> mice had more IL-10+ T-regs than <italic>HAQ</italic> mice 3. Therefore, we are excited about developing AQ-based curative therapy for SAVI patients (preventing cell death and inducing immune tolerance). Again, we thank the Reviewer for the suggestion. Additional research is ongoing.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p><p>Minor points</p><p>(1) Generation of THP1 cells with the human STING alleles is missing from methods.</p></disp-quote><p>We added the protocol in the methods (lines 380-387). THP-1 KO line stable expressing WT STING was first described by Weikang Tao’s group 10.</p><disp-quote content-type="editor-comment"><p>(2) Some abbreviations are not expanded (CDA).</p></disp-quote><p>CDA is expanded as cyclic di-AMP (e.g. line 375).</p><p>References.</p><p>(1) Patel, S. <italic>et al.</italic> The Common R71H-G230A-R293Q Human TMEM173 Is a Null Allele. <italic>J Immunol</italic> 198, 776-787 (2017).</p><p>(2) Sebastian, M. <italic>et al.</italic> Obesity and STING1 genotype associate with 23-valent pneumococcal vaccination efficacy. <italic>JCI Insight</italic> 5 (2020).</p><p>(3) Mansouri, S. <italic>et al.</italic> MPYS Modulates Fatty Acid Metabolism and Immune Tolerance at Homeostasis Independent of Type I IFNs. <italic>J Immunol</italic> 209, 2114-2132 (2022).</p><p>(4) Sivick, K. E. <italic>et al.</italic> Comment on &quot;The Common R71H-G230A-R293Q Human TMEM173 Is a Null Allele&quot;. <italic>J Immunol</italic> 198, 4183-4185 (2017).</p><p>(5) Gulen, M. F. <italic>et al.</italic> Signalling strength determines proapoptotic functions of STING. <italic>Nat Commun</italic> 8, 427 (2017).</p><p>(6) Kabelitz, D. <italic>et al.</italic> Signal strength of STING activation determines cytokine plasticity and cell death in human monocytes. <italic>Sci Rep</italic> 12, 17827 (2022).</p><p>(7) Murthy, A. M. V., Robinson, N. &amp; Kumar, S. Crosstalk between cGAS-STING signaling and cell death. <italic>Cell Death Differ</italic> 27, 2989-3003 (2020).</p><p>(8) Kuhl, N. <italic>et al.</italic> STING agonism turns human T cells into interferon-producing cells but impedes their functionality. <italic>EMBO Rep</italic> 24, e55536 (2023).</p><p>(9) Li, C., Liu, J., Hou, W., Kang, R. &amp; Tang, D. STING1 Promotes Ferroptosis Through MFN1/2-Dependent Mitochondrial Fusion. <italic>Front Cell Dev Biol</italic> 9, 698679 (2021).</p><p>(10) Song, C. <italic>et al.</italic> SHR1032, a novel STING agonist, stimulates anti-tumor immunity and directly induces AML apoptosis. <italic>Sci Rep</italic> 12, 8579 (2022).</p><p>(11) Jin, L. <italic>et al.</italic> Identification and characterization of a loss-of-function human MPYS variant. <italic>Genes Immun</italic> 12, 263-269 (2011).</p><p>(12) Yi, G. <italic>et al.</italic> Single nucleotide polymorphisms of human STING can affect innate immune response to cyclic dinucleotides. <italic>PLoS One</italic> 8, e77846 (2013).</p><p>(13) Patel, S. <italic>et al.</italic> Response to Comment on &quot;The Common R71H-G230A-R293Q Human TMEM173 Is a Null Allele&quot;. <italic>J Immunol</italic> 198, 4185-4188 (2017).</p><p>(14) Gao, K. M. <italic>et al.</italic> Endothelial cell expression of a STING gain-of-function mutation initiates pulmonary lymphocytic infiltration. <italic>Cell Rep</italic> 43, 114114 (2024).</p><p>(15) Gao, K. M., Motwani, M., Tedder, T., Marshak-Rothstein, A. &amp; Fitzgerald, K. A. Radioresistant cells initiate lymphocyte-dependent lung inflammation and IFNgamma-dependent mortality in STING gain-of-function mice. <italic>Proc Natl Acad Sci U S A</italic> 119, e2202327119 (2022).</p><p>(16) Hu, W. <italic>et al.</italic> Regulatory T cells function in established systemic inflammation and reverse fatal autoimmunity. <italic>Nat Immunol</italic> 22, 1163-1174 (2021).</p><p>(17) Monroe, K. M. <italic>et al.</italic> IFI16 DNA sensor is required for death of lymphoid CD4 T cells abortively infected with HIV. <italic>Science</italic> 343, 428-432 (2014).</p><p>(18) Doitsh, G. <italic>et al.</italic> Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. <italic>Nature</italic> 505, 509-514 (2014).</p><p>(19) Jakobsen, M. R., Olagnier, D. &amp; Hiscott, J. Innate immune sensing of HIV-1 infection. <italic>Curr Opin HIV AIDS</italic> 10, 96-102 (2015).</p><p>(20) Silvin, A. &amp; Manel, N. Innate immune sensing of HIV infection. <italic>Curr Opin Immunol</italic> 32, 54-60 (2015).</p><p>(21) Altfeld, M. &amp; Gale, M., Jr. Innate immunity against HIV-1 infection. <italic>Nat Immunol</italic> 16, 554-562 (2015).</p><p>(22) Krapp, C., Jonsson, K. &amp; Jakobsen, M. R. STING dependent sensing - Does HIV actually care? <italic>Cytokine Growth Factor Rev</italic> 40, 68-76 (2018).</p><p>(23) Liu, Y. <italic>et al.</italic> Activated STING in a vascular and pulmonary syndrome. <italic>N Engl J Med</italic> 371, 507-518 (2014).</p><p>(24) Luksch, H. <italic>et al.</italic> STING-associated lung disease in mice relies on T cells but not type I interferon. <italic>J Allergy Clin Immunol</italic> 144, 254-266 e258 (2019).</p><p>(25) Stinson, W. A. <italic>et al.</italic> The IFN-gamma receptor promotes immune dysregulation and disease in STING gain-of-function mice. <italic>JCI Insight</italic> 7 (2022).</p><p>(26) Warner, J. D. <italic>et al.</italic> STING-associated vasculopathy develops independently of IRF3 in mice. <italic>J Exp Med</italic> 214, 3279-3292 (2017).</p><p>(27) Fremond, M. L. <italic>et al.</italic> Overview of STING-Associated Vasculopathy with Onset in Infancy (SAVI) Among 21 Patients. <italic>J Allergy Clin Immunol Pract</italic> 9, 803-818 e811 (2021).</p></body></sub-article></article>